{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:55:55Z","timestamp":1790636155432,"version":"4.1.0"},"reference-count":360,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EMDR\/SG\/15\/2023-5901"],"award-info":[{"award-number":["EMDR\/SG\/15\/2023-5901"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41417-026-01070-3","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:05:23Z","timestamp":1787213123000},"page":"1150-1176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced gene editing technologies for oncology mechanisms, applications, and clinical implementation"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2996-034X","authenticated-orcid":false,"given":"Soham","family":"Bindu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2664-293X","authenticated-orcid":false,"given":"Archishman","family":"Ash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-6688","authenticated-orcid":false,"given":"Koustav","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"1070_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/0023677221994613","volume":"56","author":"SE Tr\u00f6der","year":"2022","unstructured":"Tr\u00f6der SE, Zevnik B. History of genome editing: from meganucleases to CRISPR. Lab Anim. 2022;56:60\u20138.","journal-title":"Lab Anim"},{"key":"1070_CR2","doi-asserted-by":"publisher","first-page":"7676","DOI":"10.1039\/D3CC00559C","volume":"59","author":"D Matsumoto","year":"2023","unstructured":"Matsumoto D, Nomura W. The history of genome editing: advances from the interface of chemistry and biology. Chem Commun. 2023;59:7676\u201384.","journal-title":"Chem Commun"},{"key":"1070_CR3","unstructured":"Gene editing | Definition, History, and CRISPR-Cas9 | Britannica. 2025. Available from: https:\/\/www.britannica.com\/science\/gene-editing."},{"key":"1070_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","volume":"21","author":"JS Brown","year":"2023","unstructured":"Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Mol Cancer Res. 2023;21:1142.","journal-title":"Mol Cancer Res"},{"key":"1070_CR5","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3390\/cancers17132102","volume":"17","author":"G Colonna","year":"2025","unstructured":"Colonna G. Overcoming barriers in cancer biology research: current limitations and solutions. Cancers. 2025;17:2102.","journal-title":"Cancers"},{"key":"1070_CR6","first-page":"1","volume":"10","author":"Y Li","year":"2025","unstructured":"Li Y, Liu F, Cai Q, Deng L, Ouyang Q, Zhang XHF, et al. Invasion and metastasis in cancer: molecular insights and therapeutic targets. Signal Transduct Target Ther. 2025;10:1\u201338.","journal-title":"Signal Transduct Target Ther"},{"key":"1070_CR7","doi-asserted-by":"crossref","unstructured":"Kontomanolis EN, Koutras A, Syllaios A, Schizas D, Mastoraki A, Garmpis N, et al. Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review. Anticancer Res. 2020;40:6009\u201315. Available from: https:\/\/ar.iiarjournals.org\/content\/40\/11\/6009.","DOI":"10.21873\/anticanres.14622"},{"key":"1070_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.582","volume":"5","author":"TC Dakal","year":"2024","unstructured":"Dakal TC, Dhabhai B, Pant A, Moar K, Chaudhary K, Yadav V, et al. Oncogenes and tumor suppressor genes: functions and roles in cancers. MedComm. 2024;5. e582.","journal-title":"MedComm"},{"key":"1070_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/cancers17071082","volume":"17","author":"SR Singh","year":"2025","unstructured":"Singh SR, Bhaskar R, Ghosh S, Yarlagadda B, Singh KK, Verma P, et al. Exploring the genetic orchestra of cancer: the interplay between oncogenes and tumor-suppressor genes. Cancers. 2025;17:1082.","journal-title":"Cancers"},{"key":"1070_CR10","first-page":"1539","volume":"26","author":"H Liu","year":"2011","unstructured":"Liu H, Xing Y, Yang S, Tian D. Remarkable difference of somatic mutation patterns between oncogenes and tumor suppressor genes. Oncol Rep. 2011;26:1539\u201346.","journal-title":"Oncol Rep"},{"key":"1070_CR11","unstructured":"Cancer genes - PubMed. 2025. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8460509\/."},{"key":"1070_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/0749-2081(92)90006-O","volume":"8","author":"JW Yarbro","year":"1992","unstructured":"Yarbro JW. Oncogenes and cancer suppressor genes. Semin Oncol Nurs. 1992;8:30\u20139.","journal-title":"Semin Oncol Nurs"},{"key":"1070_CR13","doi-asserted-by":"crossref","unstructured":"Debela DT, Muzazu SGY, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9. Available from: https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/20503121211034366.","DOI":"10.1177\/20503121211034366"},{"key":"1070_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","volume":"16","author":"A Zafar","year":"2025","unstructured":"Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A. Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discov Oncol. 2025;16:607.","journal-title":"Discov Oncol"},{"key":"1070_CR15","first-page":"1","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9:1\u201344.","journal-title":"Signal Transduct Target Ther"},{"key":"1070_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/ph18050644","volume":"18","author":"C Sulaiman","year":"2025","unstructured":"Sulaiman C, George BP, Balachandran I, Abrahamse H. Cancer and traditional medicine: an integrative approach. Pharmaceuticals. 2025;18:644. https:\/\/www.mdpi.com\/1424-8247\/18\/5\/644\/htm.","journal-title":"Pharmaceuticals"},{"key":"1070_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156113","volume":"273","author":"S Bindu","year":"2025","unstructured":"Bindu S, Ash A, Sarkar K. Interferon alpha-2b (IFN\u03b12b) in precision oncology: innovations in delivery and combinatorial immunotherapy. Pathol Res Pract. 2025;273:156113. https:\/\/pubmed.ncbi.nlm.nih.gov\/40664017\/.","journal-title":"Pathol Res Pract"},{"key":"1070_CR18","volume":"2","author":"A Ash","year":"2025","unstructured":"Ash A, Arora P, Christopher LS, Rajkumar S, Bindu S, Sarkar K. Natural products-based cancer vaccination strategy. Research. 2025;2:100403. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050475925002738.","journal-title":"Research"},{"key":"1070_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.649896","volume":"8","author":"Y Yang","year":"2021","unstructured":"Yang Y, Xu J, Ge S, Lai L. CRISPR\/Cas: advances, limitations, and applications for precision cancer research. Front Med. 2021;8:649896.","journal-title":"Front Med"},{"key":"1070_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:1\u201311. https:\/\/www.nature.com\/articles\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"key":"1070_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.797440","volume":"10","author":"A Alnefaie","year":"2022","unstructured":"Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-Sanea MM, et al. Chimeric antigen receptor t-cells: an overview of concepts, applications, limitations, and proposed solutions. Front Bioeng Biotechnol. 2022;10:797440. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9256991\/.","journal-title":"Front Bioeng Biotechnol"},{"key":"1070_CR22","unstructured":"Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Cancer molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Available from: http:\/\/stm.sciencemag.org\/."},{"key":"1070_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/genes11070747","volume":"11","author":"O Strianese","year":"2020","unstructured":"Strianese O, Rizzo F, Ciccarelli M, Galasso G, D\u2019agostino Y, Salvati A, et al. Precision and personalized medicine: how a genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes. 2020;11:747. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7397223\/.","journal-title":"Genes"},{"key":"1070_CR24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.13005\/ojc\/400403","volume":"40","author":"A Pandey","year":"2024","unstructured":"Pandey A, Gupta SP. Personalized medicine: a comprehensive review. Orient J Chem. 2024;40:933\u201344.","journal-title":"Orient J Chem"},{"key":"1070_CR25","first-page":"476","volume":"53","author":"S Lip","year":"2025","unstructured":"Lip S, Padmanabhan S. Introduction to precision medicine. Medicina. 2025;53:476\u201382. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1357303925001070.","journal-title":"Medicina"},{"key":"1070_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.tibtech.2019.12.021","volume":"38","author":"D Ho","year":"2020","unstructured":"Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, et al. Enabling technologies for personalized and precision medicine. Trends Biotechnol. 2020;38:497. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7924935\/.","journal-title":"Trends Biotechnol"},{"key":"1070_CR27","doi-asserted-by":"crossref","unstructured":"Li X, Wang Z, Man X, Dai X, Zhou Q, Zhang S. Research advances CRISPR gene editing technology generated models in the study of epithelial ovarian carcinoma. Gynecol Oncol. 2025;195:34\u201344. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S009082582500068X.","DOI":"10.1016\/j.ygyno.2025.02.022"},{"key":"1070_CR28","volume":"1880","author":"P Garg","year":"2025","unstructured":"Garg P, Singhal G, Pareek S, Kulkarni P, Horne D, Nath A, et al. Unveiling the potential of gene editing techniques in revolutionizing Cancer treatment: a comprehensive overview. Biochim et Biophys Acta. 2025;1880:189233. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0304419X24001641.","journal-title":"Biochim et Biophys Acta"},{"key":"1070_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01925-5","volume":"23","author":"M Chehelgerdi","year":"2024","unstructured":"Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024;23:1\u201345. https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01925-5.","journal-title":"Mol Cancer"},{"key":"1070_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0044-1785234","volume":"11","author":"ND Kolanu","year":"2024","unstructured":"Kolanu ND. CRISPR\u2013Cas9 gene editing: curing genetic diseases by inherited epigenetic modifications. Glob Med Genet. 2024;11:113. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10980556\/.","journal-title":"Glob Med Genet"},{"key":"1070_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2022.1067144","volume":"4","author":"KP Das","year":"2023","unstructured":"Das KP. Chandra J. Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: current progress and challenges. Front Med Technol. 2023;4:1067144. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9853978\/.","journal-title":"Front Med Technol"},{"key":"1070_CR32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s12672-025-02469-4","volume":"16","author":"P Samathoti","year":"2025","unstructured":"Samathoti P, Kumarachari RK, Bukke SPN, Rajasekhar ESK, Jaiswal AA, Eftekhari Z. The role of nanomedicine and artificial intelligence in cancer health care: individual applications and emerging integrations\u2014a narrative review. Discov Oncol. 2025;16:697. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12061837\/.","journal-title":"Discov Oncol"},{"key":"1070_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12668-025-01980-w","volume":"15","author":"M Shirzad","year":"2025","unstructured":"Shirzad M, Shaban M, Mohammadzadeh V, Rahdar A, Fathi-karkan S, Hoseini ZS, et al. Artificial intelligence-assisted design of nanomedicines for breast cancer diagnosis and therapy: advances, challenges, and future directions. BioNanoScience. 2025;15:1\u201333. https:\/\/link.springer.com\/article\/10.1007\/s12668-025-01980-w.","journal-title":"BioNanoScience"},{"key":"1070_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"JK Won","year":"2020","unstructured":"Won JK, Bakhoum SF. The cytosolic DNA-sensing cGAS\u2013Sting pathway in cancer. Cancer Discov. 2020;10:26\u201339. https:\/\/pubmed.ncbi.nlm.nih.gov\/31852718\/.","journal-title":"Cancer Discov"},{"key":"1070_CR35","doi-asserted-by":"crossref","unstructured":"Tan J, Forner J, Karcher D, Bock R. DNA base editing in nuclear and organellar genomes. Trends Genet. 2022;38:1147\u201369. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168952522001767.","DOI":"10.1016\/j.tig.2022.06.015"},{"key":"1070_CR36","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.ymthe.2020.07.021","volume":"28","author":"YK Jeong","year":"2020","unstructured":"Jeong YK, Song B, Bae S. Current status and challenges of DNA base editing tools. Mol Ther. 2020;28:1938. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7474268\/.","journal-title":"Mol Ther"},{"key":"1070_CR37","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/mt.2016.10","volume":"24","author":"ML Maeder","year":"2016","unstructured":"Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther. 2016;24:430. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4786923\/.","journal-title":"Mol Ther"},{"key":"1070_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"H Li","year":"2020","unstructured":"Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5:1\u201323. https:\/\/www.nature.com\/articles\/s41392-019-0089-y.","journal-title":"Signal Transduct Target Ther"},{"key":"1070_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105338","volume":"92","author":"AAA Aljabali","year":"2024","unstructured":"Aljabali AAA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery. J Drug Deliv Sci Technol. 2024;92:105338. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1773224724000066.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1070_CR40","doi-asserted-by":"crossref","unstructured":"Pacesa M, Pelea O, Jinek M. Past, present, and future of CRISPR genome editing technologies. Cell. 2024;187:1076\u2013100. Available from: https:\/\/www.cell.com\/action\/showFullText?pii=S0092867424001119.","DOI":"10.1016\/j.cell.2024.01.042"},{"key":"1070_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther. 2021;6:1\u201335. https:\/\/www.nature.com\/articles\/s41392-021-00648-7.","journal-title":"Signal Transduct Target Ther"},{"key":"1070_CR42","doi-asserted-by":"publisher","first-page":"a023754","DOI":"10.1101\/cshperspect.a023754","volume":"8","author":"T Gaj","year":"2016","unstructured":"Gaj T, Sirk SJ, Shui SL, Liu J. Genome-editing technologies: principles and applications. Cold Spring Harb Perspect Biol. 2016;8:a023754. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5131771\/.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1070_CR43","doi-asserted-by":"crossref","unstructured":"Woods DS, Sears CR, Turchi JJ. Recognition of DNA termini by the c-terminal region of the Ku80 and the DNA-dependent protein kinase catalytic subunit. PLoS ONE. 2015;15:10.","DOI":"10.1371\/journal.pone.0127321"},{"key":"1070_CR44","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.3390\/ijms22084134","volume":"22","author":"S Zahid","year":"2021","unstructured":"Zahid S, El Dahan MS, Iehl F, Fern\u00e1ndez-Varela P, Le Du MH, Ropars V, et al. The multifaceted roles of Ku70\/80. Int J Mol Sci. 2021;22:4134. https:\/\/www.mdpi.com\/1422-0067\/22\/8\/4134\/htm.","journal-title":"Int J Mol Sci"},{"key":"1070_CR45","doi-asserted-by":"publisher","first-page":"499.","DOI":"10.1093\/nar\/gkaf499","volume":"53","author":"Y Wang","year":"2025","unstructured":"Wang Y, Czap MS, Kim H, Masaka PM, Wang H, Beg MA, et al. The mammalian Ku70 C-terminus SAP domain is required to repair DNA damage. Nucleic Acids Res. 2025;53:499. https:\/\/doi.org\/10.1093\/nar\/gkaf499.","journal-title":"Nucleic Acids Res"},{"key":"1070_CR46","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.molcel.2023.01.012","volume":"83","author":"CJ Buehl","year":"2023","unstructured":"Buehl CJ, Goff NJ, Hardwick SW, Gellert M, Blundell TL, Yang W, et al. Two distinct long-range synaptic complexes promote different aspects of end processing prior to repair of DNA breaks by non-homologous end joining. Mol Cell. 2023;83:698\u2013714.e4. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1097276523000321.","journal-title":"Mol Cell"},{"key":"1070_CR47","doi-asserted-by":"publisher","first-page":"100133","DOI":"10.1016\/j.crbiot.2023.100133","volume":"5","author":"K Chae","year":"2023","unstructured":"Chae K, Overcash JM, Dawson C, Valentin C, Tsujimoto H, Myles KM, et al. CRISPR-based gene editing of non-homologous end joining factors biases DNA repair pathway choice toward single-strand annealing in Aedes aegypti. Curr Res Biotechnol. 2023;5:100133. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2590262823000151#s0005.","journal-title":"Curr Res Biotechnol"},{"key":"1070_CR48","doi-asserted-by":"crossref","unstructured":"Oh DH. Mechanism of genome editing tools and their application to genetic inheritance disorders. Glob Med Genet. 2024;11:319\u201329. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2699940425000323.","DOI":"10.1055\/s-0044-1790558"},{"key":"1070_CR49","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","volume":"10","author":"F Uddin","year":"2020","unstructured":"Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol. 2020;10:1387. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7427626\/.","journal-title":"Front Oncol"},{"key":"1070_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40694-024-00180-7","volume":"11","author":"S Fritsche","year":"2024","unstructured":"Fritsche S, Reinfurt A, Fronek F, Steiger MG. NHEJ and HDR can occur simultaneously during gene integration into the genome of Aspergillus niger. Fungal Biol Biotechnol. 2024;11:10. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11301975\/.","journal-title":"Fungal Biol Biotechnol"},{"key":"1070_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.388","volume":"4","author":"J Tan","year":"2023","unstructured":"Tan J, Sun X, Zhao H, Guan H, Gao S, Zhou PK. Double-strand DNA break repair: molecular mechanisms and therapeutic targets. MedComm. 2023;4:e388. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10556206\/.","journal-title":"MedComm"},{"key":"1070_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep23549","volume":"6","author":"Y Miyaoka","year":"2016","unstructured":"Miyaoka Y, Berman JR, Cooper SB, Mayerl SJ, Chan AH, Zhang B, et al. Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing. Sci Rep. 2016;6:1\u201312. https:\/\/www.nature.com\/articles\/srep23549.","journal-title":"Sci Rep"},{"key":"1070_CR53","doi-asserted-by":"crossref","unstructured":"Gray DH, Santos J, Keir AG, Villegas I, Maddock S, Trope EC, et al. A comparison of DNA repair pathways to achieve a site-specific gene modification of the Bruton\u2019s tyrosine kinase gene. Mol Ther Nucleic Acids. 2022;27:505\u201316. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2162253121003176.","DOI":"10.1016\/j.omtn.2021.12.014"},{"key":"1070_CR54","doi-asserted-by":"crossref","unstructured":"Rahman E. An overview of gene therapy and editing and the differences between them. 2023. Available from: https:\/\/research-archive.org\/index.php\/rars\/preprint\/view\/324.","DOI":"10.58445\/rars.324"},{"key":"1070_CR55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/B978-0-323-89837-9.00006-1","volume":"1","author":"S Dwivedi","year":"2022","unstructured":"Dwivedi S, Purohit P, Vasudeva A, Kumar M, Agrawal R, Sheikh NA, et al. Gene therapy and gene editing in healthcare. Biotechnol Healthc, Vol 1: Technol Innov. 2022;1:147\u201375. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/B9780323898379000061.","journal-title":"Biotechnol Healthc, Vol 1: Technol Innov"},{"key":"1070_CR56","doi-asserted-by":"crossref","unstructured":"Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther. 2016;24:430\u201346. Available from: https:\/\/www.cell.com\/action\/showFullText?pii=S1525001616309613.","DOI":"10.1038\/mt.2016.10"},{"key":"1070_CR57","doi-asserted-by":"crossref","unstructured":"Brunetti-Pierri N. Gene therapy and gene editing. Handbook of clinical adult genetics and genomics: a practice-based approach. 2020;463\u201377. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/B9780128173442000307.","DOI":"10.1016\/B978-0-12-817344-2.00030-7"},{"key":"1070_CR58","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s12033-024-01070-4","volume":"67","author":"O Volodina","year":"2025","unstructured":"Volodina O, Smirnikhina S. The future of gene therapy: a review of in vivo and ex vivo delivery methods for genome editing-based therapies. Mol Biotechnol. 2025;67:425\u201337. https:\/\/link.springer.com\/article\/10.1007\/s12033-024-01070-4.","journal-title":"Mol Biotechnol"},{"key":"1070_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413006","volume":"12","author":"J Lv","year":"2025","unstructured":"Lv J, Fan Q, Zhang Y, Zhou X, Yu P, Yu X, et al. A serum-resistant polymer with exceptional endosomal escape and mRNA delivery efficacy for CRISPR gene therapy. Adv Sci. 2025;12:2413006. https:\/\/doi.org\/10.1002\/advs.202413006.","journal-title":"Adv Sci"},{"key":"1070_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-56048-w","volume":"16","author":"SJ Park","year":"2025","unstructured":"Park SJ, Ju S, Jung WJ, Jeong TY, Yoon DE, Lee JH, et al. Robust genome editing activity and the applications of enhanced miniature CRISPR-Cas12f1. Nat Commun. 2025;16:1\u201312. https:\/\/www.nature.com\/articles\/s41467-025-56048-w1.","journal-title":"Nat Commun"},{"key":"1070_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2020.100983","volume":"22","author":"AAJ Suleiman","year":"2021","unstructured":"Suleiman AAJ, Saedi WY, Muhaidi MJ. Widely used gene editing strategies in cancer treatment a systematic review. Gene Rep. 2021;22:100983. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S2452014420303976.","journal-title":"Gene Rep"},{"key":"1070_CR62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40169-020-0268-z","volume":"9","author":"C Ashmore-Harris","year":"2020","unstructured":"Ashmore-Harris C, Fruhwirth GO. The clinical potential of gene editing as a tool to engineer cell-based therapeutics. Clin Transl Med. 2020;9:15. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7007464\/.","journal-title":"Clin Transl Med"},{"key":"1070_CR63","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.2174\/0113892010307288240526071810","volume":"26","author":"M Manikishore","year":"2024","unstructured":"Manikishore M, Maurya SK, Rathee S, Patil UK. Genome editing approaches using zinc finger nucleases (ZFNs) for the treatment of motor neuron diseases. Curr Pharm Biotechnol. 2024;26:1514\u201331. https:\/\/www.benthamdirect.com\/content\/journals\/cpb\/10.2174\/0113892010307288240526071810.","journal-title":"Curr Pharm Biotechnol"},{"key":"1070_CR64","doi-asserted-by":"publisher","unstructured":"Chivukula J, Ponnachan B, Kumar D, Nagella P. Structure and mechanism of zinc-finger nuclease-mediated genome editing in plants. Genome editing for crop improvement: theory and methodology. 2025;35\u201346. Available from: https:\/\/doi.org\/10.1079\/9781800622517.0003?download=true.","DOI":"10.1079\/9781800622517.0003"},{"key":"1070_CR65","doi-asserted-by":"crossref","unstructured":"Dreier B, Fuller RP, Segal DJ, Lund CV, Blancafort P, Huber A, et al. Development of zinc finger domains for recognition of the 5\u2032-CNN-3\u2032 family DNA sequences and their use in the construction of artificial transcription factors. J Biol Chem. 2005;280:35588\u201397. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925819482355.","DOI":"10.1074\/jbc.M506654200"},{"key":"1070_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddiscovery.2017.71","volume":"3","author":"M Cassandri","year":"2017","unstructured":"Cassandri M, Smirnov A, Novelli F, Pitolli C, Agostini M, Malewicz M, et al. Zinc-finger proteins in health and disease. Cell Death Discov. 2017;3:1\u201312. https:\/\/www.nature.com\/articles\/cddiscovery201771","journal-title":"Cell Death Discov"},{"key":"1070_CR67","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ymthe.2021.04.003","volume":"30","author":"A Miccio","year":"2021","unstructured":"Miccio A, Antoniou P, Ciura S, Kabashi E. Novel genome-editing-based approaches to treat motor neuron diseases: promises and challenges. Mol Ther. 2021;30:47. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8753272\/.","journal-title":"Mol Ther"},{"key":"1070_CR68","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/onc.2015.320","volume":"35","author":"M Pieraccioli","year":"2016","unstructured":"Pieraccioli M, Nicolai S, Antonov A, Somers J, Malewicz M, Melino G, et al. ZNF281 contributes to the DNA damage response by controlling the expression of XRCC2 and XRCC4. Oncogene. 2016;35:2592\u2013601. https:\/\/pubmed.ncbi.nlm.nih.gov\/26300006\/.","journal-title":"Oncogene"},{"key":"1070_CR69","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1101\/gad.246579.114","volume":"28","author":"LD Boxer","year":"2014","unstructured":"Boxer LD, Barajas B, Tao S, Zhang J, Khavari PA. Znf750 interacts with KLF4 and RCOR1, KDM1A, and CTBP1\/2 chromatin regulators to repress epidermal progenitor genes and induce differentiation genes. Genes Dev. 2014;28:2013\u201326. https:\/\/pubmed.ncbi.nlm.nih.gov\/25228645\/.","journal-title":"Genes Dev"},{"key":"1070_CR70","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000476068","volume":"93","author":"R Otsuka","year":"2017","unstructured":"Otsuka R, Akutsu Y, Sakata H, Hanari N, Murakami K, Kano M, et al. ZNF750 expression as a novel candidate biomarker of chemoradiosensitivity in esophageal squamous cell carcinoma. Oncology. 2017;93:197\u2013203. https:\/\/pubmed.ncbi.nlm.nih.gov\/28558382\/.","journal-title":"Oncology"},{"key":"1070_CR71","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.devcel.2011.12.001","volume":"22","author":"GL Sen","year":"2012","unstructured":"Sen GL, Boxer LD, Webster DE, Bussat RT, Qu K, Zarnegar BJ, et al. ZNF750 is a p63 target gene that induces KLF4 to drive terminal epidermal differentiation. Dev Cell. 2012;22:669\u201377. https:\/\/pubmed.ncbi.nlm.nih.gov\/22364861\/.","journal-title":"Dev Cell"},{"key":"1070_CR72","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1038\/onc.2016.377","volume":"36","author":"M Hazawa","year":"2017","unstructured":"Hazawa M, Lin DC, Handral H, Xu L, Chen Y, Jiang YY, et al. ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma. Oncogene. 2017;36:2243\u201354. https:\/\/pubmed.ncbi.nlm.nih.gov\/27819679\/.","journal-title":"Oncogene"},{"key":"1070_CR73","doi-asserted-by":"crossref","unstructured":"Cohen I, Birnbaum RY, Leibson K, Taube R, Sivan S, Birk OS. ZNF750 is expressed in differentiated keratinocytes and regulates epidermal late differentiation genes. PLoS One. 2012;7. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22936986\/.","DOI":"10.1371\/journal.pone.0042628"},{"key":"1070_CR74","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ng1813","volume":"38","author":"RY Birnbaum","year":"2006","unstructured":"Birnbaum RY, Zvulunov A, Hallel-Halevy D, Cagnano E, Finer G, Ofir R, et al. Seborrhea-like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein. Nat Genet. 2006;38:749\u201351. https:\/\/pubmed.ncbi.nlm.nih.gov\/16751772\/.","journal-title":"Nat Genet"},{"key":"1070_CR75","doi-asserted-by":"crossref","unstructured":"Birnbaum RY, Hayashi G, Cohen I, Poon A, Chen H, Lam ET, et al. Association analysis identifies ZNF750 regulatory variants in psoriasis. BMC Med Genet. 2011;12. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22185198\/.","DOI":"10.1186\/1471-2350-12-167"},{"key":"1070_CR76","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/sj.onc.1209769","volume":"26","author":"JS Zhang","year":"2007","unstructured":"Zhang JS, Gong A, Young CYF. ZNF185, an actin-cytoskeleton-associated growth inhibitory LIM protein in prostate cancer. Oncogene. 2007;26:111\u201322. https:\/\/pubmed.ncbi.nlm.nih.gov\/16799630\/.","journal-title":"Oncogene"},{"key":"1070_CR77","doi-asserted-by":"crossref","unstructured":"Bibi R, Varshetha L, Lahary RK, Namburi J, Laskar FA, Sarkar K. Epidrugs in cancer: mechanisms, applications, and future direction. Clin Transl Oncol. 2025. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/41062905\/.","DOI":"10.1007\/s12094-025-04064-z"},{"key":"1070_CR78","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1006\/bbrc.1997.6310","volume":"233","author":"T Taniuchi","year":"1997","unstructured":"Taniuchi T, Mortensen ER, Ferguson A, Greenson J, Merchant JL. Overexpression of ZBP-89, a zinc finger DNA-binding protein, in gastric cancer. Biochem Biophys Res Commun. 1997;233:154\u201360. https:\/\/pubmed.ncbi.nlm.nih.gov\/9144414\/.","journal-title":"Biochem Biophys Res Commun"},{"key":"1070_CR79","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00280-005-0063-y","volume":"57","author":"M Serova","year":"2006","unstructured":"Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, et al. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharm. 2006;57:491\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/16075278\/.","journal-title":"Cancer Chemother Pharm"},{"key":"1070_CR80","unstructured":"p53-Independent induction of apoptosis in human melanoma cells by a bcl-2\/bcl-xL bispecific antisense oligonucleotide - PubMed. 2025. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11350916\/."},{"key":"1070_CR81","doi-asserted-by":"publisher","first-page":"26516","DOI":"10.1074\/jbc.M110.212506","volume":"286","author":"S Meruvu","year":"2011","unstructured":"Meruvu S, Hugendubler L, Mueller E. Regulation of adipocyte differentiation by the zinc finger protein ZNF638. J Biol Chem. 2011;286:26516\u201323. https:\/\/pubmed.ncbi.nlm.nih.gov\/21602272\/.","journal-title":"J Biol Chem"},{"key":"1070_CR82","doi-asserted-by":"crossref","unstructured":"Li J, Ao J, Li K, Zhang J, Li Y, Zhang L, et al. ZNF32 contributes to the induction of multidrug resistance by regulating TGF-\u03b2 receptor 2 signaling in lung adenocarcinoma. Cell Death Dis. 2016;7. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27763636\/.","DOI":"10.1038\/cddis.2016.328"},{"key":"1070_CR83","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1006\/geno.1997.4810","volume":"43","author":"NS Heiss","year":"1997","unstructured":"Heiss NS, Gloeckner G, B\u00e4chner D, Kioschis P, Klauck SM, Hinzmann B, et al. Genomic structure of a novel LIM domain gene (ZNF185) in Xq28 and comparisons with the orthologous murine transcript. Genomics. 1997;43:329\u201338. https:\/\/pubmed.ncbi.nlm.nih.gov\/9268636\/.","journal-title":"Genomics"},{"key":"1070_CR84","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1038\/cdd.2011.52","volume":"18","author":"PC Pao","year":"2011","unstructured":"Pao PC, Huang NK, Liu YW, Yeh SH, Lin ST, Hsieh CP, et al. A novel RING finger protein, Znf179, modulates cell cycle exit and neuronal differentiation of P19 embryonal carcinoma cells. Cell Death Differ. 2011;18:1791\u2013804. https:\/\/pubmed.ncbi.nlm.nih.gov\/21566658\/.","journal-title":"Cell Death Differ"},{"key":"1070_CR85","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","volume":"144","author":"JH Shin","year":"2011","unstructured":"Shin JH, Ko HS, Kang H, Lee Y, Lee YIL, Pletinkova O, et al. PARIS (ZNF746) repression of PGC-1\u03b1 contributes to neurodegeneration in parkinson\u2019s disease. Cell. 2011;144:689\u2013702. https:\/\/pubmed.ncbi.nlm.nih.gov\/21376232\/.","journal-title":"Cell"},{"key":"1070_CR86","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.1093\/nar\/gki912","volume":"33","author":"S Durai","year":"2005","unstructured":"Durai S, Mani M, Kandavelou K, Wu J, Porteus MH, Chandrasegaran S. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res. 2005;33:5978\u201390. https:\/\/doi.org\/10.1093\/nar\/gki912.","journal-title":"Nucleic Acids Res"},{"key":"1070_CR87","doi-asserted-by":"publisher","first-page":"1572.","DOI":"10.3389\/fpls.2016.01572","volume":"7","author":"A Forsyth","year":"2016","unstructured":"Forsyth A, Weeks T, Richael C, Duan H. Transcription activator-like effector nucleases (TALEN)-mediated targeted DNA insertion in potato plants. Front Plant Sci. 2016;7:1572. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5078815\/.","journal-title":"Front Plant Sci"},{"key":"1070_CR88","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/bs.pmbts.2017.04.006","volume":"149","author":"H Bi","year":"2017","unstructured":"Bi H, Yang B. Gene editing With TALEN and CRISPR\/Cas in rice. Prog Mol Biol Transl Sci. 2017;149:81\u201398.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"1070_CR89","unstructured":"TALEN and CRISPR\/Cas genome editing systems: tools of discovery - PubMed. 2025. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25349712\/."},{"key":"1070_CR90","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397\u2013405.","journal-title":"Trends Biotechnol"},{"key":"1070_CR91","doi-asserted-by":"publisher","unstructured":"Xu H. Advances in CRISPR-Cas9 technology for tumor therapy. MedScience. 2024;1. Available from: https:\/\/doi.org\/10.61173\/bk6wsg49.","DOI":"10.61173\/bk6wsg49"},{"key":"1070_CR92","doi-asserted-by":"publisher","unstructured":"Mandal S, Tiwari PK. Gene therapy and gene editing for cancer therapeutics. Research anthology on bioinformatics, genomics, and computational biology. 2024;711\u2013800. Available from: https:\/\/doi.org\/10.4018\/979-8-3693-3026-5.ch033.","DOI":"10.4018\/979-8-3693-3026-5.ch033"},{"key":"1070_CR93","doi-asserted-by":"publisher","unstructured":"Zhang KW, Wang D, Cai H, Cao MQ, Zhang YY, Zhuang PY, et al. IL-6 plays a crucial role in epithelial-mesenchymal transition and pro-metastasis induced by sorafenib in liver cancer. Oncol Rep. 2021;45. Available from: https:\/\/doi.org\/10.3892\/or.2021.7926.","DOI":"10.3892\/or.2021.7926"},{"key":"1070_CR94","doi-asserted-by":"publisher","unstructured":"Shankar S, Sreekumar A, Prasad D, Das AV, Pillai MR. Genome editing of oncogenes with ZFNs and TALENs: Caveats in nuclease design. Cancer Cell Int. 2018;18:169. Available from: https:\/\/doi.org\/10.1186\/s12935-018-0666-0.","DOI":"10.1186\/s12935-018-0666-0"},{"key":"1070_CR95","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00439-016-1678-2","volume":"135","author":"R Benjamin","year":"2016","unstructured":"Benjamin R, Berges BK, Solis-Leal A, Igbinedion O, Strong CL, Schiller MR. TALEN gene editing takes aim at HIV. Hum Genet. 2016;135:1059\u201370.","journal-title":"Hum Genet"},{"key":"1070_CR96","doi-asserted-by":"crossref","unstructured":"Shankar S, Prasad D, Sanawar R, Das AV, Pillai MR. TALEN-based HPV-E7 editing triggers necrotic cell death in cervical cancer cells. Sci Rep. 2017;7. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28710417\/.","DOI":"10.1038\/s41598-017-05696-0"},{"key":"1070_CR97","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1172\/JCI78206","volume":"125","author":"Z Hu","year":"2015","unstructured":"Hu Z, Ding W, Zhu D, Yu L, Jiang X, Wang X, et al. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J Clin Investig. 2015;125:425\u201336.","journal-title":"J Clin Investig"},{"key":"1070_CR98","doi-asserted-by":"publisher","unstructured":"Aghamiri S, Talaei S, Roshanzamiri S, Zandsalimi F, Fazeli E, Aliyu M, et al. Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy. Expert Opin Drug Deliv. 2020;17:753\u2013766. https:\/\/doi.org\/10.1080\/17425247.2020.1747429.","DOI":"10.1080\/17425247.2020.1747429"},{"key":"1070_CR99","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1016\/j.ymthe.2024.08.018","volume":"32","author":"S Dharani","year":"2024","unstructured":"Dharani S, Cho H, Fernandez JP, Juillerat A, Valton J, Duchateau P, et al. TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity. Mol Ther. 2024;32:3915\u201331. https:\/\/www.cell.com\/action\/showFullText?pii=S1525001624005409.","journal-title":"Mol Ther"},{"key":"1070_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-30896-2","volume":"13","author":"S Jo","year":"2022","unstructured":"Jo S, Das S, Williams A, Chretien AS, Pagliardini T, Le Roy A, et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN gene editing. Nat Commun. 2022;13:1\u201316. https:\/\/www.nature.com\/articles\/s41467-022-30896-2.","journal-title":"Nat Commun"},{"key":"1070_CR101","doi-asserted-by":"publisher","first-page":"71.","DOI":"10.1186\/s12943-022-01550-8","volume":"21","author":"T Lan","year":"2022","unstructured":"Lan T, Que H, Luo M, Zhao X, Wei X. Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy. Mol Cancer. 2022;21:71. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8915502\/.","journal-title":"Mol Cancer"},{"key":"1070_CR102","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1038\/bcj.2014.32","volume":"4","author":"X Wu","year":"2014","unstructured":"Wu X, Blackburn PR, Tschumper RC, Ekker SC, Jelinek DF. TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells. Blood Cancer J. 2014;4:e210. https:\/\/www.nature.com\/articles\/bcj201432.","journal-title":"Blood Cancer J"},{"key":"1070_CR103","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/0008-5472.CAN-14-0529","volume":"74","author":"S Zhang","year":"2014","unstructured":"Zhang S, Li L, Kendrick SL, Gerard RD, Zhu H. TALEN-mediated somatic mutagenesis in murine models of cancer. Cancer Res. 2014;74:5311. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4167541\/.","journal-title":"Cancer Res"},{"key":"1070_CR104","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/antibiotics8010018","volume":"8","author":"A Loureiro","year":"2019","unstructured":"Loureiro A, Da Silva GJ. CRISPR-Cas: converting A bacterial defence mechanism into a state-of-the-art genetic manipulation tool. Antibiotics. 2019;8:18. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6466564\/.","journal-title":"Antibiotics"},{"key":"1070_CR105","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.molcel.2014.03.011","volume":"54","author":"R Barrangou","year":"2014","unstructured":"Barrangou R, Marraffini LA. CRISPR-Cas systems: prokaryotes upgrade to adaptive immunity. Mol Cell. 2014;54:234. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4025954\/.","journal-title":"Mol Cell"},{"key":"1070_CR106","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.molcel.2016.08.038","volume":"64","author":"J McGinn","year":"2016","unstructured":"McGinn J, Marraffini LA. CRISPR-Cas systems optimize their immune response by specifying the site of spacer integration. Mol Cell. 2016;64:616\u201323. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1097276516305172.","journal-title":"Mol Cell"},{"key":"1070_CR107","first-page":"777","volume":"87","author":"I Gostimskaya","year":"2022","unstructured":"Gostimskaya I. CRISPR\u2013Cas9: a history of its discovery and ethical considerations of its use in genome editing. Biochem. 2022;87:777\u201388.","journal-title":"Biochem"},{"key":"1070_CR108","unstructured":"What are genome editing and CRISPR-Cas9? MedlinePlus Genetics. 2025. Available from: https:\/\/medlineplus.gov\/genetics\/understanding\/genomicresearch\/genomeediting\/."},{"key":"1070_CR109","first-page":"353","volume":"15","author":"MA Mengstie","year":"2021","unstructured":"Mengstie MA, Wondimu BZ. Mechanism and applications of CRISPR\/Cas-9-mediated genome editing. Biologics. 2021;15:353. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8388126\/.","journal-title":"Biologics"},{"key":"1070_CR110","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu Y, Li Z. CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. Comput Struct Biotechnol J. 2020;18:2401. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7508700\/.","journal-title":"Comput Struct Biotechnol J"},{"key":"1070_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1060337","volume":"14","author":"M Zakrzewska","year":"2023","unstructured":"Zakrzewska M, Burmistrz M. Mechanisms regulating the CRISPR-Cas systems. Front Microbiol. 2023;14:1060337.","journal-title":"Front Microbiol"},{"key":"1070_CR112","doi-asserted-by":"publisher","unstructured":"Acosta-Soto AF, L\u00f3pez-D\u00edaz DM, Esquivel-Ram\u00edrez J, Mora-Soriano J, Medina BL, Acosta-Soto AF, et al. Fundamentals of CRISPR-Cas9: Gene-editing technology and basics. GSC Advanced Research and Reviews, 2024;20:042\u2013049. Available from: https:\/\/doi.org\/10.30574\/gscarr.2024.20.1.0223.","DOI":"10.30574\/gscarr.2024.20.1.0223"},{"key":"1070_CR113","doi-asserted-by":"crossref","unstructured":"Bandyopadhyay A, Kancharla N, Javalkote VS, Dasgupta S, Brutnell TP. CRISPR-Cas12a (Cpf1): a versatile tool in the plant genome editing toolbox for agricultural advancement. Front Plant Sci. 2020;11:584151. https:\/\/www.frontiersin.org.","DOI":"10.3389\/fpls.2020.584151"},{"key":"1070_CR114","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12915-022-01296-1","volume":"20","author":"H Huang","year":"2022","unstructured":"Huang H, Huang G, Tan Z, Hu Y, Shan L, Zhou J, et al. Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity. BMC Biol. 2022;20:91. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9040236\/.","journal-title":"BMC Biol"},{"key":"1070_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-98965-y","volume":"11","author":"MS Schubert","year":"2021","unstructured":"Schubert MS, Thommandru B, Woodley J, Turk R, Yan S, Kurgan G, et al. Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair. Sci Rep. 2021;11:1\u201315. https:\/\/www.nature.com\/articles\/s41598-021-98965-y.","journal-title":"Sci Rep"},{"key":"1070_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-34736-1","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang J, Rowe D, Subedi P, Zhang W, Suelter T, Valent B, et al. CRISPR-Cas12a-induced DNA double-strand breaks are repaired by multiple pathways with different mutation profiles in Magnaporthe oryzae. Nat Commun. 2022;13:1\u201318. https:\/\/www.nature.com\/articles\/s41467-022-34736-1.","journal-title":"Nat Commun"},{"key":"1070_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.mec.2019.e00112","volume":"10","author":"Z Yang","year":"2020","unstructured":"Yang Z, Edwards H, Xu P. CRISPR-Cas12a\/Cpf1-assisted precise, efficient and multiplexed genome-editing in Yarrowia lipolytica. Metab Eng Commun. 2020;10:e00112. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2214030119300252.","journal-title":"Metab Eng Commun"},{"key":"1070_CR118","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/pbi.12982","volume":"17","author":"K Lee","year":"2018","unstructured":"Lee K, Zhang Y, Kleinstiver BP, Guo JA, Aryee MJ, Miller J, et al. Activities and specificities of CRISPR\/Cas9 and Cas12a nucleases for targeted mutagenesis in maize. Plant Biotechnol J. 2018;17:362. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6320322\/.","journal-title":"Plant Biotechnol J"},{"key":"1070_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.algal.2024.103796","volume":"84","author":"A Ferenczi","year":"2024","unstructured":"Ferenczi A, Fellbaum M, Chew YP, Kidner C, Molnar A. Comparison of CRISPR\/Cas9 and Cas12a for gene editing in Chlamydomonas reinhardtii. Algal Res. 2024;84:103796. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2211926424004089.","journal-title":"Algal Res"},{"key":"1070_CR120","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","volume":"65","author":"VE Hillary","year":"2022","unstructured":"Hillary VE, Ceasar SA. A review on the mechanism and applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 proteins utilized for genome engineering. Mol Biotechnol. 2022;65:311. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9512960\/.","journal-title":"Mol Biotechnol"},{"key":"1070_CR121","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11248-021-00247-w","volume":"30","author":"A Ghorbani","year":"2021","unstructured":"Ghorbani A, Hadifar S, Salari R, Izadpanah K, Burmistrz M, Afsharifar A, et al. A short overview of CRISPR-Cas technology and its application in viral disease control. Transgenic Res. 2021;30:221. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8027712\/.","journal-title":"Transgenic Res"},{"key":"1070_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2022.127000","volume":"259","author":"FO Fapohunda","year":"2022","unstructured":"Fapohunda FO, Qiao S, Pan Y, Wang H, Liu Y, Chen Q, et al. CRISPR Cas system: a strategic approach in detection of nucleic acids. Microbiol Res. 2022;259:127000. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0944501322000404.","journal-title":"Microbiol Res"},{"key":"1070_CR123","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41589-024-01593-6","volume":"20","author":"H Yang","year":"2024","unstructured":"Yang H, Patel DJ. Structures, mechanisms and applications of RNA-centric CRISPR\u2013Cas13. Nat Chem Biol. 2024;20:673\u201388. https:\/\/www.nature.com\/articles\/s41589-024-01593-6.","journal-title":"Nat Chem Biol"},{"key":"1070_CR124","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1126\/science.adq0553","volume":"385","author":"PH Yoon","year":"1979","unstructured":"Yoon PH, Zhang Z, Loi KJ, Adler BA, Lahiri A, Vohra K, et al. Structure-guided discovery of ancestral CRISPR-Cas13 ribonucleases. Science. 1979;385:538\u201343.","journal-title":"Science"},{"key":"1070_CR125","doi-asserted-by":"crossref","unstructured":"Yu J, Jin J, Kwon E, Jang H, Choi SK, Kim D, et al. Programmable RNA acetylation with CRISPR\u2013Cas13. Nat Chem Biol. 2025. https:\/\/phys.org\/news\/2025-06-crispr-cas13-modification-desired-rna.html.","DOI":"10.1038\/s41589-025-01922-3"},{"key":"1070_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1011399","volume":"13","author":"Z Huang","year":"2022","unstructured":"Huang Z, Fang J, Zhou M, Gong Z, Xiang T. CRISPR-Cas13: a new technology for the rapid detection of pathogenic microorganisms. Front Microbiol. 2022;13:1011399. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9650447\/.","journal-title":"Front Microbiol"},{"key":"1070_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.866800","volume":"10","author":"R Gupta","year":"2022","unstructured":"Gupta R, Ghosh A, Chakravarti R, Singh R, Ravichandiran V, Swarnakar S, et al. Cas13d: a new molecular scissor for transcriptome engineering. Front Cell Dev Biol. 2022;10:866800. https:\/\/www.nobelprize.org\/.","journal-title":"Front Cell Dev Biol"},{"key":"1070_CR128","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s13238-020-00700-2","volume":"11","author":"B He","year":"2020","unstructured":"He B, Peng W, Huang J, Zhang H, Zhou Y, Yang X, et al. Modulation of metabolic functions through Cas13d-mediated gene knockdown in liver. Protein Cell. 2020;11:518\u201324.","journal-title":"Protein Cell"},{"key":"1070_CR129","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.cell.2024.01.035","volume":"187","author":"V Tieu","year":"2024","unstructured":"Tieu V, Sotillo E, Bjelajac JR, Chen C, Malipatlolla M, Guerrero JA, et al. A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell. 2024;187:1278\u20131295.e20. Feb 29.","journal-title":"Cell"},{"key":"1070_CR130","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/nar\/gkaf986","volume":"53","author":"X Chen","year":"2025","unstructured":"Chen X, He Y, Guo M, Liu S, Li Y, Zeng F, et al. Mechanistic insights into Cas13d enzymes from cryo-EM structures of CasRx and DjCas13d. Nucleic Acids Res. 2025;53:13\u20134. https:\/\/doi.org\/10.1093\/nar\/gkaf986.","journal-title":"Nucleic Acids Res"},{"key":"1070_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.866800","volume":"10","author":"R Gupta","year":"2022","unstructured":"Gupta R, Ghosh A, Chakravarti R, Singh R, Ravichandiran V, Swarnakar S, et al. Cas13d: a new molecular scissor for transcriptome engineering. Front Cell Dev Biol. 2022;10:866800. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9008242\/.","journal-title":"Front Cell Dev Biol"},{"key":"1070_CR132","doi-asserted-by":"crossref","unstructured":"Wei J, Lotfy P, Faizi K, Baungaard S, Gibson E, Wang E, et al. Deep learning and CRISPR-Cas13d ortholog discovery for optimized RNA targeting. 2021. Available from: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.09.14.460134.","DOI":"10.1101\/2021.09.14.460134"},{"key":"1070_CR133","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41587-023-01830-8","volume":"42","author":"HH Wessels","year":"2024","unstructured":"Wessels HH, Stirn A, M\u00e9ndez-Mancilla A, Kim EJ, Hart SK, Knowles DA, et al. Prediction of on-target and off-target activity of CRISPR\u2013Cas13d guide RNAs using deep learning. Nat Biotechnol. 2024;42:628\u201337.","journal-title":"Nat Biotechnol"},{"key":"1070_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-36316-3","volume":"14","author":"X Cheng","year":"2023","unstructured":"Cheng X, Li Z, Shan R, Li Z, Wang S, Zhao W, et al. Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches. Nat Commun. 2023;14:1\u201314. https:\/\/www.nature.com\/articles\/s41467-023-36316-3.","journal-title":"Nat Commun"},{"key":"1070_CR135","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.molcel.2018.02.028","volume":"70","author":"WX Yan","year":"2018","unstructured":"Yan WX, Chong S, Zhang H, Makarova KS, Koonin EV, Cheng DR, et al. Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein. Mol Cell. 2018;70:327\u2013339.e5.","journal-title":"Mol Cell"},{"key":"1070_CR136","unstructured":"Cas13d: Small RNA-targeting CRISPR enzymes for transcriptome engineering. 2025. Available from: https:\/\/blog.addgene.org\/cas13d-small-efficient-rna-targeting-crispr-enzymes."},{"key":"1070_CR137","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41551-021-00760-7","volume":"5","author":"MM Kaminski","year":"2021","unstructured":"Kaminski MM, Abudayyeh OO, Gootenberg JS, Zhang F, Collins JJ. CRISPR-based diagnostics. Nat Biomed Eng. 2021;5:643\u201356. https:\/\/www.nature.com\/articles\/s41551-021-00760-7.","journal-title":"Nat Biomed Eng"},{"key":"1070_CR138","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1038\/s41596-019-0210-2","volume":"14","author":"MJ Kellner","year":"2019","unstructured":"Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc. 2019;14:2986. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6956564\/.","journal-title":"Nat Protoc"},{"key":"1070_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.snr.2025.100358","volume":"10","author":"Zakiyyah","year":"2025","unstructured":"Zakiyyah, Irkham SN, Sima KSP, Kharismasari CY, Xi M, Gaffar S, et al. CRISPR-Cas13a-powered electrochemical biosensors for RNA-based disease diagnostic and monitoring. Sens Actuators Rep. 2025;10:100358. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666053925000761.","journal-title":"Sens Actuators Rep"},{"key":"1070_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acssynbio.2c00496","volume":"12","author":"A Ghouneimy","year":"2022","unstructured":"Ghouneimy A, Mahas A, Marsic T, Aman R, Mahfouz M. CRISPR-based diagnostics: challenges and potential solutions toward point-of-care applications. ACS Synth Biol. 2022;12:1. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9872163\/.","journal-title":"ACS Synth Biol"},{"key":"1070_CR141","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1158\/0008-5472.CAN-18-0785","volume":"78","author":"JT Granados-Riveron","year":"2018","unstructured":"Granados-Riveron JT, Aquino-Jarquin G. CRISPR-Cas13 precision transcriptome engineering in cancer. Cancer Res. 2018;78:4107\u201313. https:\/\/pubmed.ncbi.nlm.nih.gov\/30021724\/.","journal-title":"Cancer Res"},{"key":"1070_CR142","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3892\/ijo.2025.5748","volume":"66","author":"KS Allemailem","year":"2025","unstructured":"Allemailem KS, Rahmani AH, Almansour NM, Aldakheel FM, Albalawi GM, Albalawi GM, et al. Current updates on the structural and functional aspects of the CRISPR\/Cas13 system for RNA targeting and editing: a next-generation tool for cancer management (Review). Int J Oncol. 2025;66:42. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12068846\/.","journal-title":"Int J Oncol"},{"key":"1070_CR143","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1093\/nar\/gkz267","volume":"47","author":"VA Truong","year":"2019","unstructured":"Truong VA, Hsu MN, Kieu Nguyen NT, Lin MW, Shen CC, Lin CY, et al. CRISPRai for simultaneous gene activation and inhibition to promote stem cell chondrogenesis and calvarial bone regeneration. Nucleic Acids Res. 2019;47:e74. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6648329\/.","journal-title":"Nucleic Acids Res"},{"key":"1070_CR144","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.3390\/plants10102055","volume":"10","author":"CKS Karlson","year":"2021","unstructured":"Karlson CKS, Mohd-noor SN, Nolte N, Tan BC. CRISPR\/dCas9-based systems: mechanisms and applications in plant sciences. Plants. 2021;10:2055. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8540305\/.","journal-title":"Plants"},{"key":"1070_CR145","doi-asserted-by":"publisher","unstructured":"Ren C, Li H, Liu Y, Li S, Liang Z. Highly efficient activation of endogenous gene in grape using CRISPR\/dCas9-based transcriptional activators. Hortic Res. 2022;9. Available from: https:\/\/doi.org\/10.1093\/hr\/uhab037.","DOI":"10.1093\/hr\/uhab037"},{"key":"1070_CR146","unstructured":"CRISPRa and CRISPRi: gene expression modulation | OriGene Technologies Inc.2025. Available from: https:\/\/www.origene.com\/products\/gene-expression\/crispr-cas9\/crispra-crispri."},{"key":"1070_CR147","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nature14136","volume":"517","author":"S Konermann","year":"2014","unstructured":"Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nat. 2014;517:583. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4420636\/.","journal-title":"Nat"},{"key":"1070_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154532","volume":"116","author":"I Stafeev","year":"2021","unstructured":"Stafeev I, Michurina S, Truong VA, Mamontova E, Shevchenko E, Ratner E, et al. Proof-of-concept for CRISPRai-mediated simultaneous activation of UCP-1 and inhibition of CIDEC expressions in preadipocytes: effects on white adipogenic differentiation. Metab. 2021;116:154532. https:\/\/www.metabolismjournal.com\/action\/showFullText?pii=S0026049520303966.","journal-title":"Metab"},{"key":"1070_CR149","doi-asserted-by":"publisher","first-page":"e0270008","DOI":"10.1371\/journal.pone.0270008","volume":"17","author":"K Omachi","year":"2022","unstructured":"Omachi K, Miner JH. Comparative analysis of dCas9-VP64 variants and multiplexed guide RNAs mediating CRISPR activation. PLoS One. 2022;17:e0270008. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9239446\/.","journal-title":"PLoS One"},{"key":"1070_CR150","doi-asserted-by":"crossref","unstructured":"Omachi K, Miner JH. Comparative analysis and rational design of dCas9-VP64 variants for CRISPR activation.Preprint in 2021. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.08.13.456279v1.","DOI":"10.1101\/2021.08.13.456279"},{"key":"1070_CR151","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/cbic.201800823","volume":"20","author":"D Cunningham-Bryant","year":"2019","unstructured":"Cunningham-Bryant D, Sun J, Fernandez B, Zalatan JG. CRISPR\u2013Cas-mediated chemical control of transcriptional dynamics in yeast. ChemBioChem. 2019;20:1519\u201323. https:\/\/doi.org\/10.1002\/cbic.201800823.","journal-title":"ChemBioChem"},{"key":"1070_CR152","doi-asserted-by":"crossref","unstructured":"Clark T, Waller MA, Loo L, Moreno CL, Denes CE, Neely GG. CRISPR activation screens: navigating technologies and applications. Trends Biotechnol. 2024;42:1017\u201334. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0167779924000362.","DOI":"10.1016\/j.tibtech.2024.02.007"},{"key":"1070_CR153","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3390\/ijms26051804","volume":"26","author":"ME Siviski","year":"2025","unstructured":"Siviski ME, Bercovitch R, Pyburn K, Potts C, Pande SR, Gartner CA, et al. CTHRC1 expression results in secretion-mediated, SOX9-dependent suppression of adipogenesis: implications for the regulatory role of newly identified CTHRC1\u2009+\u2009\/PDGFR-Alpha+ stromal cells of adipose. Int J Mol Sci. 2025;26:1804. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11898434\/.","journal-title":"Int J Mol Sci"},{"key":"1070_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21124283","volume":"21","author":"MA Ambele","year":"2020","unstructured":"Ambele MA, Dhanraj P, Giles R, Pepper MS. Adipogenesis: a complex interplay of multiple molecular determinants and pathways. Int J Mol Sci. 2020;21:1\u201327. https:\/\/pubmed.ncbi.nlm.nih.gov\/32560163\/.","journal-title":"Int J Mol Sci"},{"key":"1070_CR155","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/nar\/gkaf809","volume":"53","author":"V Migliori","year":"2025","unstructured":"Migliori V, Bruntraeger MB, Gyulev IS, Lichou F, Burgold T, Gitterman DP, et al. ONE-STEP tagging: a versatile method for rapid site-specific integration by simultaneous reagent delivery. Nucleic Acids Res. 2025;53:13\u20134. https:\/\/doi.org\/10.1093\/nar\/gkaf809.","journal-title":"Nucleic Acids Res"},{"key":"1070_CR156","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401797","volume":"11","author":"Y Liu","year":"2024","unstructured":"Liu Y, Kong J, Liu G, Li Z, Xiao Y, Liu Y, et al. Precise gene knock-in tools with minimized risk of DSBs: a trend for gene manipulation. Adv Sci. 2024;11:2401797. https:\/\/doi.org\/10.1002\/advs.202401797.","journal-title":"Adv Sci"},{"key":"1070_CR157","doi-asserted-by":"crossref","unstructured":"Wang JY, Doudna JA. CRISPR technology: a decade of genome editing is only the beginning. Science. 2023;379. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.add8643.","DOI":"10.1126\/science.add8643"},{"key":"1070_CR158","unstructured":"https:\/\/tlo.mit.edu\/industry-entrepreneurs\/available-technologies\/programmable-addition-site-specific-targeting Programmable Addition Via Site-Specific Targeting Elements (PASTE)\u2009|\u2009MIT Technology Licensing Office. 2025."},{"key":"1070_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-023-00943-1","volume":"30","author":"NS Mikkelsen","year":"2023","unstructured":"Mikkelsen NS, Bak RO. Enrichment strategies to enhance genome editing. J Biomed Sci. 2023;30:1\u201321. https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-023-00943-1.","journal-title":"J Biomed Sci"},{"key":"1070_CR160","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.omtn.2023.04.012","volume":"32","author":"KM Fichter","year":"2023","unstructured":"Fichter KM, Setayesh T, Malik P. Strategies for precise gene edits in mammalian cells. Mol Ther Nucleic Acids. 2023;32:536. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10192336\/.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1070_CR161","first-page":"21","volume":"18","author":"MA Mengstie","year":"2024","unstructured":"Mengstie MA, Azezew MT, Dejenie TA, Teshome AA, Admasu FT, Teklemariam AB, et al. Recent advancements in reducing the off-target effect of CRISPR-Cas9 genome editing. Biologics. 2024;18:21. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10802171\/.","journal-title":"Biologics"},{"key":"1070_CR162","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41551-024-01227-1","volume":"9","author":"S Pandey","year":"2025","unstructured":"Pandey S, Gao XD, Krasnow NA, McElroy A, Tao YA, Duby JE, et al. Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing. Nat Biomed Eng. 2025;9:22\u201339. https:\/\/www.nature.com\/articles\/s41551-024-01227-1.","journal-title":"Nat Biomed Eng"},{"key":"1070_CR163","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008","volume":"37","author":"C Xue","year":"2021","unstructured":"Xue C, Greene EC. DNA repair pathway choices in CRISPR-Cas9 mediated genome editing. Trends Genet. 2021;37:639. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8187289\/.","journal-title":"Trends Genet"},{"key":"1070_CR164","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","volume":"41","author":"MTN Yarnall","year":"2023","unstructured":"Yarnall MTN, Ioannidi EI, Schmitt-Ulms C, Krajeski RN, Lim J, Villiger L, et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat Biotechnol. 2023;41:500\u201312. https:\/\/pubmed.ncbi.nlm.nih.gov\/36424489\/.","journal-title":"Nat Biotechnol"},{"key":"1070_CR165","doi-asserted-by":"crossref","unstructured":"Chen X, Du J, Yun S, Xue C, Yao Y, Rao S. Recent advances in CRISPR-Cas9-based genome insertion technologies. Mol Ther Nucleic Acids. 2024;35:102138. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2162253124000258 Mar 12cited2025 Oct 5] Available from.","DOI":"10.1016\/j.omtn.2024.102138"},{"key":"1070_CR166","unstructured":"Gwon LW, Badon IW, Lee Y, Kim HJ, Lee SH. Advances in large-scale DNA engineering with the CRISPR system. Exp Mol Med. 2025 ;1\u201311. Available from: https:\/\/www.nature.com\/articles\/s12276-025-01530-0."},{"key":"1070_CR167","unstructured":"Gupta PK, Kumar S. Third-generation novel technologies for gene editing. Trends Biotechnol. 2025. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0167779925002732."},{"key":"1070_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-025-03756-7","volume":"26","author":"R Zhu","year":"2025","unstructured":"Zhu R, Ren C, Bao Z. Fueling chromosomal gene diversification and artificial evolution with CRISPR. Genome Biol. 2025;26:1\u201327. https:\/\/genomebiology.biomedcentral.com\/articles\/10.1186\/s13059-025-03756-7.","journal-title":"Genome Biol"},{"key":"1070_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2023.100491","volume":"28","author":"X Wang","year":"2023","unstructured":"Wang X, Xu G, Johnson WA, Qu Y, Yin D, Ramkissoon N, et al. Long sequence insertion via CRISPR\/Cas gene-editing with transposase, recombinase, and integrase. Curr Opin Biomed Eng. 2023;28:100491. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10976843\/.","journal-title":"Curr Opin Biomed Eng"},{"key":"1070_CR170","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.1016\/S0021-9258(19)62687-6","volume":"261","author":"R Sklar","year":"1986","unstructured":"Sklar R, Altman D, Sager R. An endonuclease from Chlamydomonas reinhardtii that cleaves the sequence TATA. J Biol Chem. 1986;261:6806\u201310. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0021925819626876.","journal-title":"J Biol Chem"},{"key":"1070_CR171","doi-asserted-by":"crossref","unstructured":"Seligman LM, Stephens KM, Savage JH, Monnat RJ. Genetic analysis of the Chlamydomonas reinhardtii I-CreI mobile intron homing system in Escherichia coli. Genet. 1997;147:1653\u201364. Deccited 2025 Oct 9]. Available from https:\/\/pubmed.ncbi.nlm.nih.gov\/9409828\/.","DOI":"10.1093\/genetics\/147.4.1653"},{"key":"1070_CR172","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41467-024-45246-7","volume":"15","author":"A Poulhazan","year":"2024","unstructured":"Poulhazan A, Arnold AA, Mentink-Vigier F, Muszy\u0144ski A, Azadi P, Halim A, et al. Molecular-level architecture of Chlamydomonas reinhardtii\u2019s glycoprotein-rich cell wall. Nat Commun. 2024;15:986. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10837150\/.","journal-title":"Nat Commun"},{"key":"1070_CR173","unstructured":"https:\/\/www.nature.com\/articles\/d43747-022-00219-x A precise platform for clinical gene editing. 2025."},{"key":"1070_CR174","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/s42255-023-00932-6","volume":"5","author":"WK Shoop","year":"2023","unstructured":"Shoop WK, Lape J, Trum M, Powell A, Sevigny E, Mischler A, et al. Efficient elimination of MELAS-associated m.3243\u2009G mutant mitochondrial DNA by an engineered mitoARCUS nuclease. Nat Metab. 2023;5:2169. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10730414\/.","journal-title":"Nat Metab"},{"key":"1070_CR175","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf961","volume":"53","author":"LC Resly","year":"2025","unstructured":"Resly LC, Tubbs AL, Vogel AJ, Hux JA, MacDonald IA, Harris J, et al. High-efficiency homology-directed insertion into the genome using the engineered homing endonuclease ARCUS. Nucleic Acids Res. 2025;53:gkaf961. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12497482\/.","journal-title":"Nucleic Acids Res"},{"key":"1070_CR176","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1016\/j.ymthe.2022.05.013","volume":"30","author":"CL Gorsuch","year":"2022","unstructured":"Gorsuch CL, Nemec P, Yu M, Xu S, Han D, Smith J, et al. Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo. Mol Ther. 2022;30:2909\u201322. https:\/\/pubmed.ncbi.nlm.nih.gov\/35581938\/.","journal-title":"Mol Ther"},{"key":"1070_CR177","first-page":"507","volume":"66","author":"MA McCall","year":"2025","unstructured":"McCall MA, Jalligampala A, Wang W, Prestigiacomo J, Jantz D, Bartsevich V, et al. Successful expansion of late-stage disease treatment of P23H human RHO (hRHO) using ARCUS nuclease gene editing in a pig model of Autosomal Dominant Retinitis Pigmentosa (adRP). Invest Ophthalmol Vis Sci. 2025;66:507\u2013507.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1070_CR178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-23561-7","volume":"12","author":"U Zekonyte","year":"2021","unstructured":"Zekonyte U, Bacman SR, Smith J, Shoop W, Pereira CV, Tomberlin G, et al. Mitochondrial- targeted meganuclease as a platform to eliminate mutant mtDNA in vivo. Nat Commun. 2021;12:1\u201311. https:\/\/www.nature.com\/articles\/s41467-021-23561-7.","journal-title":"Nat Commun"},{"key":"1070_CR179","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-1-4939-1862-1_9","volume":"1239","author":"S Boisse","year":"2015","unstructured":"Boisse S, Scharenberg AM. Assembly and characterization of megaTALs for hyperspecific genome engineering applications. Methods Mol Biol. 2015;1239:171\u201396. https:\/\/pubmed.ncbi.nlm.nih.gov\/25408406\/.","journal-title":"Methods Mol Biol"},{"key":"1070_CR180","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/nar\/gkt1224","volume":"42","author":"S Boissel","year":"2014","unstructured":"Boissel S, Jarjour J, Astrakhan A, Adey A, Gouble A, Duchateau P, et al. megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res. 2014;42:2591\u2013601. https:\/\/pubmed.ncbi.nlm.nih.gov\/24285304\/.","journal-title":"Nucleic Acids Res"},{"key":"1070_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.ggedit.2021.100007","volume":"2","author":"S Becker","year":"2021","unstructured":"Becker S, Boch J. TALE and TALEN genome editing technologies. Gene Genome Editing. 2021;2:100007. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666388021000071.","journal-title":"Gene Genome Editing"},{"key":"1070_CR182","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2022.892769","volume":"4","author":"Y Lu","year":"2022","unstructured":"Lu Y, Happi Mbakam C, Song B, Bendavid E, Tremblay JP. Improvements of nuclease and nickase gene modification techniques for the treatment of genetic diseases. Front Genome Ed. 2022;4:892769.","journal-title":"Front Genome Ed"},{"key":"1070_CR183","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/d41573-020-00096-y","volume":"19","author":"A Mullard","year":"2020","unstructured":"Mullard A. Gene-editing pipeline takes off. Nat Rev Drug Discov. 2020;19:367\u201372.","journal-title":"Nat Rev Drug Discov"},{"key":"1070_CR184","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/ctm2.34","volume":"10","author":"N Zheng","year":"2020","unstructured":"Zheng N, Li L, Wang X. Molecular mechanisms, off-target activities, and clinical potentials of genome editing systems. Clin Transl Med. 2020;10:412. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7240848\/.","journal-title":"Clin Transl Med"},{"key":"1070_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.xplc.2025.101427","volume":"6","author":"J Liu","year":"2025","unstructured":"Liu J, Zhang R, Chai N, Su L, Zheng Z, Liu T, et al. Programmable genome engineering and gene modifications for plant biodesign. Plant Commun. 2025;6:101427. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2590346225001890.","journal-title":"Plant Commun"},{"key":"1070_CR186","doi-asserted-by":"publisher","first-page":"10355","DOI":"10.3390\/ijms221910355","volume":"22","author":"NG Castro","year":"2021","unstructured":"Castro NG, Bjelic J, Malhotra G, Huang C, Alsaffar SH. Comparison of the feasibility, efficiency, and safety of genome editing technologies. Int J Mol Sci. 2021;22:10355. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8509008\/.","journal-title":"Int J Mol Sci"},{"key":"1070_CR187","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1073\/pnas.1321030111","volume":"111","author":"R Takeuchi","year":"2014","unstructured":"Takeuchi R, Choi M, Stoddard BL. Redesign of extensive protein\u2013DNA interfaces of meganucleases using iterative cycles of in vitro compartmentalization. Proc Natl Acad Sci USA. 2014;111:4061\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1070_CR188","doi-asserted-by":"crossref","unstructured":"Fanton A, Bartie LJ, Martins JQ, Tran VQ, Goudy L, Durrant MG, et al. Site-specific DNA insertion into the human genome with engineered recombinases. Preprint in 2024 https:\/\/www.biorxiv.org\/content\/10.1101\/2024.11.01.621560v1.","DOI":"10.1101\/2024.11.01.621560"},{"key":"1070_CR189","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1038\/s41587-023-02121-y","volume":"42","author":"L Mukhametzyanova","year":"2024","unstructured":"Mukhametzyanova L, Schmitt LT, Torres-Rivera J, Rojo-Romanos T, Lansing F, Paszkowski-Rogacz M, et al. Activation of recombinases at specific DNA loci by zinc-finger domain insertions. Nat Biotechnol. 2024;42:1844\u201354. https:\/\/www.nature.com\/articles\/s41587-023-02121-y.","journal-title":"Nat Biotechnol"},{"key":"1070_CR190","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-35614-6","volume":"13","author":"LT Schmitt","year":"2022","unstructured":"Schmitt LT, Paszkowski-Rogacz M, Jug F, Buchholz F. Prediction of designer-recombinases for DNA editing with generative deep learning. Nat Commun. 2022;13:1\u201312. https:\/\/www.nature.com\/articles\/s41467-022-35614-6.","journal-title":"Nat Commun"},{"key":"1070_CR191","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-12800-7","volume":"10","author":"BH Weinberg","year":"2019","unstructured":"Weinberg BH, Cho JH, Agarwal Y, Pham NTH, Caraballo LD, Walkosz M, et al. High-performance chemical- and light-inducible recombinases in mammalian cells and mice. Nat Commun. 2019;10:1\u201310. https:\/\/www.nature.com\/articles\/s41467-019-12800-7.","journal-title":"Nat Commun"},{"key":"1070_CR192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-46755-1","volume":"15","author":"BD Huang","year":"2024","unstructured":"Huang BD, Kim D, Yu Y, Wilson CJ. Engineering intelligent chassis cells via recombinase-based MEMORY circuits. Nat Commun. 2024;15:1\u201317. https:\/\/www.nature.com\/articles\/s41467-024-46755-1.","journal-title":"Nat Commun"},{"key":"1070_CR193","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1016\/j.cell.2025.07.011","volume":"188","author":"C Sun","year":"2025","unstructured":"Sun C, Li H, Liu Y, Li Y, Gao R, Shi X, et al. Iterative recombinase technologies for efficient and precise genome engineering across kilobase to megabase scales. Cell. 2025;188:4693\u20134710.e15. https:\/\/www.cell.com\/action\/showFullText?pii=S0092867425008001.","journal-title":"Cell"},{"key":"1070_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1267378","volume":"11","author":"K Kim","year":"2023","unstructured":"Kim K, Kang M, Cho BK. Systems and synthetic biology-driven engineering of live bacterial therapeutics. Front Bioeng Biotechnol. 2023;11:1267378.","journal-title":"Front Bioeng Biotechnol"},{"key":"1070_CR195","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/antibiotics13050436","volume":"13","author":"Y Wang","year":"2024","unstructured":"Wang Y, Hunt A, Danziger L, Drwiega EN. A comparison of currently available and investigational fecal microbiota transplant products for recurrent clostridioides difficile infection. Antibiotics. 2024;13:436. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11117328\/.","journal-title":"Antibiotics"},{"key":"1070_CR196","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1080\/17460913.2024.2403892","volume":"19","author":"P Berry","year":"2024","unstructured":"Berry P, Khanna S. Fecal microbiota spores, live-brpk (VOWSTTM\/VOS) for prevention of recurrent Clostridioides difficile infection. Future Microbiol. 2024;19:1519\u201328.","journal-title":"Future Microbiol"},{"key":"1070_CR197","doi-asserted-by":"crossref","unstructured":"HL D, AW D, GS T. Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone. Therap Adv Gastroenterol. 2024;17. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38800353\/.","DOI":"10.1177\/17562848241253089"},{"key":"1070_CR198","doi-asserted-by":"crossref","unstructured":"Buecherl L, Myers CJ. Engineering genetic circuits: advancements in genetic design automation tools and standards for synthetic biology. Curr Opin Microbiol. 2022;68. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35588683\/.","DOI":"10.1016\/j.mib.2022.102155"},{"key":"1070_CR199","doi-asserted-by":"crossref","unstructured":"Sarac B, Y\u00fccer S, Ciftci F. Synthetic biology-driven biosensors for healthcare applications: A roadmap toward programmable and intelligent diagnostics. Biosens Bioelectron. 2026;291. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/41027168\/.","DOI":"10.1016\/j.bios.2025.118036"},{"key":"1070_CR200","doi-asserted-by":"crossref","unstructured":"Ren H, Qin M, Zhang L, Li Z, Li Y, He Q, et al. Modular engineering of a synthetic biology-based platform for sustainable bioremediation of residual antibiotics in aquatic environments. Engineering. 2025.https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2095809925001973.","DOI":"10.1016\/j.eng.2025.03.033"},{"key":"1070_CR201","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1021\/acssynbio.4c00340","volume":"13","author":"A Pandey","year":"2024","unstructured":"Pandey A. IWBDA 2022: toward a modular future of synthetic biology driven by bio-design automation. ACS Synth Biol. 2024;13:1583\u20135.","journal-title":"ACS Synth Biol"},{"key":"1070_CR202","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.csbj.2025.05.001","volume":"27","author":"C Li","year":"2025","unstructured":"Li C, Zou Q, Li J, Feng H. Prediction of CRISPR-Cas9 on-target activity based on a hybrid neural network. Comput Struct Biotechnol J. 2025;27:2098\u2013106. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2001037025001643.","journal-title":"Comput Struct Biotechnol J"},{"key":"1070_CR203","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s12276-025-01462-9","volume":"57","author":"MG Kim","year":"2025","unstructured":"Kim MG, Go MJ, Kang SH, Jeong SH, Lim K. Revolutionizing CRISPR technology with artificial intelligence. Exp Mol Med. 2025;57:1419\u201331. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40745000.","journal-title":"Exp Mol Med"},{"key":"1070_CR204","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-0716-4690-8_14","volume":"2952","author":"S Khammampalli","year":"2025","unstructured":"Khammampalli S, Vindal V. Artificial intelligence in crispr-cas systems: a review of tool applications. Methods Mol Biol. 2025;2952:243\u201357.","journal-title":"Methods Mol Biol"},{"key":"1070_CR205","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-1-0716-4690-8_16","volume":"2952","author":"S Pandey","year":"2025","unstructured":"Pandey S, Choudhari JK, Tripathi A, Singh A, Antony A, Chouhan U. Artificial intelligence-based genome editing in CRISPR\/Cas9. Methods Mol Biol. 2025;2952:273\u201382. https:\/\/pubmed.ncbi.nlm.nih.gov\/40553339\/.","journal-title":"Methods Mol Biol"},{"key":"1070_CR206","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3390\/biomedicines12092158","volume":"12","author":"R Ghemrawi","year":"2024","unstructured":"Ghemrawi R, Abuamer L, Kremesh S, Hussien G, Ahmed R, Mousa W, et al. Revolutionizing cancer treatment: recent advances in immunotherapy. Biomedicines. 2024;12:2158. https:\/\/www.mdpi.com\/2227-9059\/12\/9\/2158\/htm.","journal-title":"Biomedicines"},{"key":"1070_CR207","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2020.100142","volume":"1","author":"W Gao","year":"2020","unstructured":"Gao W, Mahajan SP, Sulam J, Gray JJ. Deep learning in protein structural modeling and design. Patterns. 2020;1:100142. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7733882\/.","journal-title":"Patterns"},{"key":"1070_CR208","doi-asserted-by":"publisher","DOI":"10.1177\/25151355241305856","volume":"12","author":"M Shahzadi","year":"2024","unstructured":"Shahzadi M, Rafique H, Waheed A, Naz H, Waheed A, Zokirova FR, et al. Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives. Ther Adv Vaccines Immunother. 2024;12:25151355241305856. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11650588\/.","journal-title":"Ther Adv Vaccines Immunother"},{"key":"1070_CR209","doi-asserted-by":"publisher","DOI":"10.3389\/fmmed.2023.1250508","volume":"3","author":"N B\u00e4ckel","year":"2023","unstructured":"B\u00e4ckel N, Hort S, Kis T, Nettleton DF, Egan JR, Jacobs JJL, et al. Elaborating the potential of Artificial intelligence in automated CAR-T cell manufacturing. Front Mol Med. 2023;3:1250508. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11285580\/.","journal-title":"Front Mol Med"},{"key":"1070_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.106084","volume":"150","author":"R Zhang","year":"2022","unstructured":"Zhang R, Han X, Lei Z, Jiang C, Gul I, Hu Q, et al. RCMNet: a deep learning model assists CAR-T therapy for leukemia. Comput Biol Med. 2022;150:106084. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0010482522007922.","journal-title":"Comput Biol Med"},{"key":"1070_CR211","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5483\/BMBRep.2024-0102","volume":"58","author":"YY Jeong","year":"2025","unstructured":"Jeong YY, Han JH, Yu J, Bae S, Seo PJ. Identification of optimal adenine and cytosine base editors for genome editing in Arabidopsis and soybean. BMB Rep. 2025;58:288\u201392. https:\/\/www.bmbreports.org\/journal\/view.html?doi=10.5483\/BMBRep.2024-0102.","journal-title":"BMB Rep"},{"key":"1070_CR212","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41587-022-01533-6","volume":"41","author":"ME Neugebauer","year":"2023","unstructured":"Neugebauer ME, Hsu A, Arbab M, Krasnow NA, McElroy AN, Pandey S, et al. Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity. Nat Biotechnol. 2023;41:673\u201385. https:\/\/www.nature.com\/articles\/s41587-022-01533-6.","journal-title":"Nat Biotechnol"},{"key":"1070_CR213","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","volume":"38","author":"T Lei","year":"2024","unstructured":"Lei T, Wang Y, Zhang Y, Yang Y, Cao J, Huang J, et al. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024;38:2517\u201343. https:\/\/www.nature.com\/articles\/s41375-024-02444-y.","journal-title":"Leukemia"},{"key":"1070_CR214","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, Van Der Stegen SJC, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543:113\u20137.","journal-title":"Nature"},{"key":"1070_CR215","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","volume":"184","author":"JK Nu\u00f1ez","year":"2021","unstructured":"Nu\u00f1ez JK, Chen J, Pommier GC, Cogan JZ, Replogle JM, Adriaens C, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell. 2021;184:2503. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8376083\/.","journal-title":"Cell"},{"key":"1070_CR216","doi-asserted-by":"publisher","first-page":"e202101321","DOI":"10.26508\/lsa.202101321","volume":"5","author":"L Ding","year":"2022","unstructured":"Ding L, Schmitt LT, Brux M, S\u00fcr\u00fcn D, Augsburg M, Lansing F, et al. DNA methylation\u2013independent long-term epigenetic silencing with dCRISPR\/Cas9 fusion proteins. Life Sci Alliance. 2022;5:e202101321. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8921183\/.","journal-title":"Life Sci Alliance"},{"key":"1070_CR217","doi-asserted-by":"publisher","DOI":"10.1126\/science.ado7082","volume":"384","author":"EN Neumann","year":"2024","unstructured":"Neumann EN, Bertozzi TM, Wu E, Serack F, Harvey JW, Brauer PP, et al. Brain-wide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor. Sci. 2024;384:ado7082. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11875203\/.","journal-title":"Sci"},{"key":"1070_CR218","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy: assessment and management of toxicities. Vol. 15, Nature Reviews Clinical Oncology. Nature Publishing Group; 2018. p. 47\u201362.","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"1070_CR219","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21:1089\u2013108. https:\/\/www.nature.com\/articles\/s41423-024-01207-0.","journal-title":"Cell Mol Immunol"},{"key":"1070_CR220","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","volume":"14","author":"Z Lyu","year":"2025","unstructured":"Lyu Z, Niu S, Fang Y, Chen Y, Li YR, Yang L. Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer. Exp Hematol Oncol. 2025;14:66. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12046680\/.","journal-title":"Exp Hematol Oncol"},{"key":"1070_CR221","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jcyt.2025.04.064","volume":"27","author":"JR Caporale","year":"2025","unstructured":"Caporale JR, Naeimi Kararoudi M, Lamb MG, Lee DA. Dark NKnight rising: a current perspective on NK cell and CAR-NK cell therapy. Cytotherapy. 2025;27:812\u201325. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1465324925006875.","journal-title":"Cytotherapy"},{"key":"1070_CR222","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers14174318","volume":"14","author":"Z Pang","year":"2022","unstructured":"Pang Z, Wang Z, Li F, Feng C, Mu X. Current progress of CAR-NK therapy in cancer treatment. Cancers. 2022;14:4318. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9454439\/.","journal-title":"Cancers"},{"key":"1070_CR223","first-page":"650","volume":"28","author":"J Moscarelli","year":"2022","unstructured":"Moscarelli J, Zahavi D, Maynard R, Weiner LM. The next generation of cellular immunotherapy: CAR-NK cells. Transpl Cell Ther. 2022;28:650. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9547868\/.","journal-title":"Transpl Cell Ther"},{"key":"1070_CR224","doi-asserted-by":"publisher","first-page":"e002866","DOI":"10.1136\/jitc-2021-002866","volume":"9","author":"M Bachiller","year":"2021","unstructured":"Bachiller M, Perez-Amill L, Battram AM, Carn\u00e9 SC, Najjar A, Verhoeyen E, et al. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving CAR-T cell fitness. J Immunother Cancer. 2021;9:e002866. https:\/\/jitc.bmj.com\/content\/9\/8\/e002866.","journal-title":"J Immunother Cancer"},{"key":"1070_CR225","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428\u201333. https:\/\/www.science.org\/doi\/10.1126\/science.aaf1292.","journal-title":"Science"},{"key":"1070_CR226","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355:1423\u20137. https:\/\/www.science.org\/doi\/10.1126\/science.aaf0683.","journal-title":"Science"},{"key":"1070_CR227","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1249330","volume":"14","author":"A Razaghi","year":"2023","unstructured":"Razaghi A, Durand-Dubief M, Brusselaers N, Bj\u00f6rnstedt M. Combining PD-1\/PD-L1 blockade with type I interferon in cancer therapy. Front Immunol. 2023;14:1249330. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10484344\/.","journal-title":"Front Immunol"},{"key":"1070_CR228","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.autrev.2011.11.018","volume":"11","author":"A Kessel","year":"2012","unstructured":"Kessel A, Haj T, Peri R, Snir A, Melamed D, Sabo E, et al. Human CD19+CD25high B regulatory cells suppress proliferation of CD4\u2009+\u2009T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev. 2012;11:670\u20137.","journal-title":"Autoimmun Rev"},{"key":"1070_CR229","first-page":"1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang CH, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther. 2025;10:1\u201349. https:\/\/www.nature.com\/articles\/s41392-025-02280-1.","journal-title":"Signal Transduct Target Ther"},{"key":"1070_CR230","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1315283","volume":"15","author":"BC Cianciotti","year":"2024","unstructured":"Cianciotti BC, Magnani ZI, Ugolini A, Camisa B, Merelli I, Vavassori V, et al. TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells. Front Immunol. 2024;15:1315283.","journal-title":"Front Immunol"},{"key":"1070_CR231","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"M Das","year":"2017","unstructured":"Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276:97. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5512889\/.","journal-title":"Immunol Rev"},{"key":"1070_CR232","unstructured":"Recalibrating immune balance: CRISPR-based reengineering of CTLA-4 and PD-1 pathways. 2025. Available from: https:\/\/reseaprojournals.com\/journals\/immunology-research\/Articles\/recalibrating-immune-balance-crispr-based-reengineering-of-ctla-4-and-pd-1-pathways."},{"key":"1070_CR233","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.834002","volume":"12","author":"E Elmas","year":"2022","unstructured":"Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, et al. CRISPR gene editing of human primary NK and T cells for cancer immunotherapy. Front Oncol. 2022;12:834002. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9016158\/.","journal-title":"Front Oncol"},{"key":"1070_CR234","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1354825","volume":"15","author":"R Tao","year":"2024","unstructured":"Tao R, Han X, Bai X, Yu J, Ma Y, Chen W, et al. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology. Front Immunol. 2024;15:1354825. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10914996\/.","journal-title":"Front Immunol"},{"key":"1070_CR235","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848327","volume":"13","author":"Y Xu","year":"2022","unstructured":"Xu Y, Chen C, Guo Y, Hu S, Sun Z. Effect of CRISPR\/Cas9-edited PD-1\/PD-L1 on tumor immunity and immunotherapy. Front Immunol. 2022;13:848327. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8920996\/.","journal-title":"Front Immunol"},{"key":"1070_CR236","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1182\/bloodadvances.2022007405","volume":"7","author":"AG Mansour","year":"2023","unstructured":"Mansour AG, Teng KY, Li Z, Zhu Z, Chen H, Tian L, et al. Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia. Blood Adv. 2023;7:6225\u201339. https:\/\/pubmed.ncbi.nlm.nih.gov\/37379267\/.","journal-title":"Blood Adv"},{"key":"1070_CR237","doi-asserted-by":"crossref","unstructured":"Chen S, van den Brink MRM. Allogeneic \u201cOff-the-Shelf\u201d CAR T cells: challenges and advances. Best Pract Res Clin Haematol. 2024;37.","DOI":"10.1016\/j.beha.2024.101566"},{"key":"1070_CR238","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399. https:\/\/pubmed.ncbi.nlm.nih.gov\/31900462\/.","journal-title":"Nat Rev Drug Discov"},{"key":"1070_CR239","doi-asserted-by":"publisher","first-page":"115888","DOI":"10.1016\/j.biopha.2023.115888","volume":"169","author":"V Moradi","year":"2023","unstructured":"Moradi V, Omidkhoda A, Ahmadbeigi N. The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: an overview of clinical trials. Biomed Pharmacother. 2023;169:115888. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0753332223016864.","journal-title":"Biomed Pharmacother"},{"key":"1070_CR240","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-023-00435-w","volume":"12","author":"C Aparicio","year":"2023","unstructured":"Aparicio C, Acebal C, Gonz\u00e1lez-Vallinas M. Current approaches to develop \u201coff-the-shelf\u201d chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review. Exp Hematol Oncol. 2023;12:1\u201317. https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-023-00435-w.","journal-title":"Exp Hematol Oncol"},{"key":"1070_CR241","doi-asserted-by":"crossref","unstructured":"Dai J, Paul M, Kar UK, Park H, Kang YK, Shim G. CRISPR\/Cas9-mediated customizing strategies for adoptive T-cell therapy. Pharmaceutics. 2024;16:346. https:\/\/www.mdpi.com\/1999-4923\/16\/3\/346\/htm.","DOI":"10.3390\/pharmaceutics16030346"},{"key":"1070_CR242","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-024-00602-z","volume":"12","author":"P Song","year":"2024","unstructured":"Song P, Zhang Q, Xu Z, Shi Y, Jing R, Luo D. CRISPR\/Cas-based CAR-T cells: production and application. Biomark Res. 2024;12:1\u201312. https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-024-00602-z.","journal-title":"Biomark Res"},{"key":"1070_CR243","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2023.102112","volume":"4","author":"D Flumens","year":"2023","unstructured":"Flumens D, Campillo-Davo D, Janssens I, Roex G, De Waele J, Anguille S, et al. One-step CRISPR-Cas9-mediated knockout of native TCR\u03b1\u03b2 genes in human T cells using RNA electroporation. STAR Protoc. 2023;4:102112. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9943861\/.","journal-title":"STAR Protoc"},{"key":"1070_CR244","doi-asserted-by":"publisher","first-page":"e005845","DOI":"10.1136\/jitc-2022-005845","volume":"11","author":"V Laletin","year":"2023","unstructured":"Laletin V, Bernard PL, Costa Da Silva C, Guittard G, Nunes JA. Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets. J Immunother Cancer. 2023;11:e005845. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10231026\/.","journal-title":"J Immunother Cancer"},{"key":"1070_CR245","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41551-022-00915-0","volume":"6","author":"SJC van der Stegen","year":"2022","unstructured":"van der Stegen SJC, Lindenbergh PL, Petrovic RM, Xie H, Diop MP, Alexeeva V, et al. Generation of T-cell-receptor-negative CD8\u03b1\u03b2-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nat Biomed Eng. 2022;6:1284\u201397. https:\/\/pubmed.ncbi.nlm.nih.gov\/35941192\/.","journal-title":"Nat Biomed Eng"},{"key":"1070_CR246","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2021.102643","volume":"59","author":"OH Lee","year":"2022","unstructured":"Lee OH, Lee S, Park M, Moon S, Hwang S, Kim B, et al. Generation of a B2M homozygous knockout human somatic cell nuclear transfer-derived embryonic stem cell line using the CRISPR\/Cas9 system. Stem Cell Res. 2022;59:102643. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1873506121004906.","journal-title":"Stem Cell Res"},{"key":"1070_CR247","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3390\/biom13081178","volume":"13","author":"MH Ravindranath","year":"2023","unstructured":"Ravindranath MH, Ravindranath NM, Selvan SR, El Hilali F, Amato-Menker CJ, Filippone EJ. Cell Surface B2m-Free Human Leukocyte Antigen (HLA) Monomers and Dimers: Are They Neo-HLA Class and Proto-HLA? Biomolecules. 2023;13:1178. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10452486\/.","journal-title":"Biomolecules"},{"key":"1070_CR248","doi-asserted-by":"crossref","unstructured":"Li YR, Zhou Y, Yu J, Zhu Y, Lee D, Zhu E, et al. Engineering allo-rejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Mol Ther. 2024;32:1849\u201374. Available from: https:\/\/www.cell.com\/action\/showFullText?pii=S1525001624002211.","DOI":"10.1016\/j.ymthe.2024.04.005"},{"key":"1070_CR249","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s42003-021-02237-4","volume":"4","author":"S Petrus-Reurer","year":"2021","unstructured":"Petrus-Reurer S, Romano M, Howlett S, Jones JL, Lombardi G, Saeb-Parsy K. Immunological considerations and challenges for regenerative cellular therapies. Commun Biol. 2021;4:798. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8233383\/.","journal-title":"Commun Biol"},{"key":"1070_CR250","doi-asserted-by":"publisher","unstructured":"Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G, et al. CAR-T cell therapy in cancer: tribulations and road ahead. J Immunol Res. 2020;2020:1924379. https:\/\/doi.org\/10.1155\/2020\/1924379.","DOI":"10.1155\/2020\/1924379"},{"key":"1070_CR251","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361194","volume":"15","author":"T Li","year":"2024","unstructured":"Li T, Niu M, Zhang W, Qin S, Zhou J, Yi M. CAR-NK cells for cancer immunotherapy: recent advances and future directions. Front Immunol. 2024;15:1361194. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10884099\/.","journal-title":"Front Immunol"},{"key":"1070_CR252","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","volume":"19","author":"P Kazemian","year":"2022","unstructured":"Kazemian P, Yu SY, Thomson SB, Birkenshaw A, Leavitt BR, Ross CJD. Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components. Mol Pharm. 2022;19:1669\u201386.","journal-title":"Mol Pharm"},{"key":"1070_CR253","doi-asserted-by":"publisher","unstructured":"Wu F, Li N, Xiao Y, Palanki R, Yamagata H, Mitchell MJ, et al. Lipid nanoparticles for delivery of CRISPR gene editing components. Small Methods. 2025;2401632. Available from: https:\/\/doi.org\/10.1002\/smtd.202401632.","DOI":"10.1002\/smtd.202401632"},{"key":"1070_CR254","doi-asserted-by":"publisher","unstructured":"Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors. Front Cell Dev Biol. 2020;8:672. Available from: https:\/\/doi.org\/10.3389\/fcell.2020.00672.","DOI":"10.3389\/fcell.2020.00672"},{"key":"1070_CR255","unstructured":"Clark SB, Alsubait S. Non\u2013small cell lung cancer. StatPearls. 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562307\/."},{"key":"1070_CR256","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nat. 2023;615:687\u201396. https:\/\/www.nature.com\/articles\/s41586-022-05531-1.","journal-title":"Nat"},{"key":"1070_CR257","doi-asserted-by":"publisher","first-page":"TPS3151","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3151","volume":"38","author":"B Chmielowski","year":"2020","unstructured":"Chmielowski B, Ejadi S, Funke R, Stallings-Schmitt T, Denker M, Frohlich MW, et al. A phase Ia\/Ib, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors. J Clin Oncol. 2020;38:TPS3151\u2013TPS3151. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2020.38.15_suppl.TPS3151.","journal-title":"J Clin Oncol"},{"key":"1070_CR258","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.900825","volume":"13","author":"L Huang","year":"2022","unstructured":"Huang L, Liao Z, Liu Z, Chen Y, Huang T, Xiao H. Application and prospect of CRISPR\/Cas9 technology in reversing drug resistance of non-small cell lung cancer. Front Pharm. 2022;13:900825. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9127258\/.","journal-title":"Front Pharm"},{"key":"1070_CR259","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-022-02504-2","volume":"22","author":"B Kim","year":"2022","unstructured":"Kim B, Kim Y, Shin S, Lee ST, Cho JY, Lee KA. Application of CRISPR\/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer. Cancer Cell Int. 2022;22:1\u201311. https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-022-02504-2.","journal-title":"Cancer Cell Int"},{"key":"1070_CR260","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","volume":"79","author":"A Murtuza","year":"2019","unstructured":"Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res. 2019;79:689\u201398.","journal-title":"Cancer Res"},{"key":"1070_CR261","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-023-02656-3","volume":"25","author":"W Ding","year":"2024","unstructured":"Ding W, Yang P, Zhao X, Wang X, Liu H, Su Q, et al. Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations. Respir Res. 2024;25:1\u201311. https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02656-3.","journal-title":"Respir Res"},{"key":"1070_CR262","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113503","volume":"424","author":"N Ochi","year":"2023","unstructured":"Ochi N, Takeyama M, Miyake N, Fuchigami M, Yamane H, Fukazawa T, et al. The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics. Exp Cell Res. 2023;424:113503. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0014482723000502.","journal-title":"Exp Cell Res"},{"key":"1070_CR263","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","volume":"29","author":"J Liu","year":"2022","unstructured":"Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Ther. 2022;29:875\u20138. https:\/\/www.nature.com\/articles\/s41417-021-00383-9.","journal-title":"Cancer Gene Ther"},{"key":"1070_CR264","doi-asserted-by":"crossref","unstructured":"Rosell R, Codony-Servat J, Gonz\u00e1lez J, Santarpia M, Jain A, Shivamallu C, et al. KRAS G12C-mutant driven non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol [Internet. 2024;195:104228. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1040842823003165.","DOI":"10.1016\/j.critrevonc.2023.104228"},{"key":"1070_CR265","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02225-w","volume":"41","author":"AK Kwan","year":"2022","unstructured":"Kwan AK, Piazza GA, Keeton AB, Leite CA. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. J Exp Clin Cancer Res. 2022;41:1\u201323. https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-021-02225-w.","journal-title":"J Exp Clin Cancer Res"},{"key":"1070_CR266","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1611580","volume":"29","author":"J Moldvay","year":"2024","unstructured":"Moldvay J, T\u00edm\u00e1r J. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges. Pathol Oncol Res. 2024;29:1611580. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10794394\/.","journal-title":"Pathol Oncol Res"},{"key":"1070_CR267","first-page":"640","volume":"4","author":"P Fakour","year":"2019","unstructured":"Fakour P, Shirizadeh A, Tahamoli-Roudsari A, Solgi G. Epigenetic regulation of FOXP3 gene expression in relation to impaired function of regulatory T cells in systemic lupus erythematosus. Open Explorat. 2019;4:640\u201357. https:\/\/www.explorationpub.com\/Journals\/ei\/Article\/1003164.","journal-title":"Open Explorat"},{"key":"1070_CR268","doi-asserted-by":"publisher","unstructured":"Li M, Quintana A, Alberts E, Hung MS, Boulat V, Ripoll MM, et al. B cells in breast cancer pathology. Cancers. (Basel). 2023;15:1517. Available from: https:\/\/doi.org\/10.3390\/cancers15051517.","DOI":"10.3390\/cancers15051517"},{"key":"1070_CR269","doi-asserted-by":"publisher","first-page":"219","DOI":"10.7150\/jca.22554","volume":"9","author":"H Yang","year":"2018","unstructured":"Yang H, Jaeger ML, Walker A, Wei D, Leiker K, Weitao T. Break breast cancer addiction by CRISPR\/Cas9 genome editing. J Cancer. 2018;9:219. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5771328\/.","journal-title":"J Cancer"},{"key":"1070_CR270","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-024-01577-y","volume":"22","author":"Y Gong","year":"2024","unstructured":"Gong Y, Li H. CDK7 in breast cancer: mechanisms of action and therapeutic potential. Cell Commun Signal. 2024;22:1\u201313. https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-024-01577-y.","journal-title":"Cell Commun Signal"},{"key":"1070_CR271","doi-asserted-by":"crossref","unstructured":"McDermott MSJ, Sharko AC, Munie J, Kassler S, Melendez T, Lim CU, et al. CDK7 inhibition is effective in all the subtypes of breast cancer: determinants of response and synergy with EGFR inhibition. Cells. 2020;9. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32155786\/.","DOI":"10.3390\/cells9030638"},{"key":"1070_CR272","doi-asserted-by":"publisher","unstructured":"Chen Z, Liu Y, Lyu M, Chan CH, Sun M, Yang X, et al. Classifications of triple-negative breast cancer: insights and current therapeutic approaches. Cell Biosci. 2025;15:13. Available from: https:\/\/doi.org\/10.1186\/s13578-025-01359-0.","DOI":"10.1186\/s13578-025-01359-0"},{"key":"1070_CR273","first-page":"101","volume":"21","author":"AK Dogra","year":"2025","unstructured":"Dogra AK, Prakash A, Gupta S, Gupta M, Dogra AK, Prakash A, et al. Prognostic significance and molecular classification of triple-negative breast cancer: a systematic review. Eur J Breast Health. 2025;21:101\u201314.","journal-title":"Eur J Breast Health"},{"key":"1070_CR274","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101\u201326. https:\/\/www.nature.com\/articles\/s41573-022-00579-0.","journal-title":"Nat Rev Drug Discov"},{"key":"1070_CR275","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/genes15070903","volume":"15","author":"X Cheng","year":"2024","unstructured":"Cheng X. A comprehensive review of HER2 in cancer biology and therapeutics. Genes. 2024;15:903. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11275319\/.","journal-title":"Genes"},{"key":"1070_CR276","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/cells10020223","volume":"10","author":"MV Dieci","year":"2021","unstructured":"Dieci MV, Miglietta F, Guarneri V. Immune infiltrates in breast cancer: recent updates and clinical implications. Cells. 2021;10:223. https:\/\/www.mdpi.com\/2073-4409\/10\/2\/223\/htm.","journal-title":"Cells"},{"key":"1070_CR277","unstructured":"Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab for the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (NCT05756166) | CareAcross Lung Cancer service. 2025. Available from: https:\/\/www.careacross.com\/clinical-trials\/trial\/NCT05756166."},{"key":"1070_CR278","doi-asserted-by":"crossref","unstructured":"Hu Q, Hong Y, Qi P, Lu G, Mai X, Xu S, et al. Atlas of breast cancer-infiltrating B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. Nat Commun. 2021;12.","DOI":"10.1038\/s41467-021-22300-2"},{"key":"1070_CR279","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37:559\u201369. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.18.01010.","journal-title":"J Clin Oncol"},{"key":"1070_CR280","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast: Off J Eur Soc Mastology. 2022;66:15. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9465273\/.","journal-title":"Breast: Off J Eur Soc Mastology"},{"key":"1070_CR281","doi-asserted-by":"publisher","unstructured":"Bindu S, Bibi R, Pradeep R, Sarkar K. The evolving role of B cells in malignancies. Hum Immunol. 2025;86:111301. https:\/\/doi.org\/10.1016\/j.humimm.2025.111301.","DOI":"10.1016\/j.humimm.2025.111301"},{"key":"1070_CR282","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2024.101461","volume":"7","author":"R Shaikh","year":"2024","unstructured":"Shaikh R, Bhattacharya S, Prajapati BG. Microsatellite instability: a potential game-changer in colorectal cancer diagnosis and treatment. Results Chem. 2024;7:101461. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2211715624001577.","journal-title":"Results Chem"},{"key":"1070_CR283","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318. https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2017699.","journal-title":"N Engl J Med"},{"key":"1070_CR284","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jconrel.2020.03.015","volume":"322","author":"T Wan","year":"2020","unstructured":"Wan T, Chen Y, Pan Q, Xu X, Kang Y, Gao X, et al. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy. J Controlled Release. 2020;322:236\u201347.","journal-title":"J Controlled Release"},{"key":"1070_CR285","doi-asserted-by":"crossref","unstructured":"Peng X, Zhang T, Jia X, Wang T, Lin H, Li G, et al. Impact of a haplotype (composed of the APC, KRAS, and TP53 genes) on colorectal adenocarcinoma differentiation and patient prognosis. Cancer Genet. 2022;268\u2013269:115\u201323. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2210776222001302.","DOI":"10.1016\/j.cancergen.2022.10.002"},{"key":"1070_CR286","doi-asserted-by":"crossref","unstructured":"Lou E, Choudhry MS, Starr TK, Folsom TD, Bell J, Rathmann B, et al. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncol. 2025;26:559\u201370. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S147020452500083X.","DOI":"10.1016\/S1470-2045(25)00083-X"},{"key":"1070_CR287","doi-asserted-by":"crossref","unstructured":"Johnson MJ, Sumstad D, Folsom TD, Slipek NJ, DeFeo AP, Growe M, et al. Clinical manufacture of CRISPR\/Cas9-based cytokine-induced SH2 protein knockout tumor-infiltrating lymphocytes for gastrointestinal cancers. Cytotherapy. 2025;27. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40673842\/.","DOI":"10.1016\/j.jcyt.2025.06.007"},{"key":"1070_CR288","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118121","volume":"300","author":"W Tao","year":"2025","unstructured":"Tao W, Zhu J, Fu Z, Liu X, Tang S, Xiang H, et al. Targeted degradation of Werner syndrome helicase (WRN) via ligand-directed covalent hydrophobic tagging. Eur J Med Chem. 2025;300:118121. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0223523425008864.","journal-title":"Eur J Med Chem"},{"key":"1070_CR289","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.arr.2017.11.003","volume":"41","author":"M Lebel","year":"2018","unstructured":"Lebel M, Monnat RJ. Werner syndrome (WRN) gene variants and their association with altered function and age-associated diseases. Ageing Res Rev. 2018;41:82\u201397. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1568163717302507.","journal-title":"Ageing Res Rev"},{"key":"1070_CR290","doi-asserted-by":"publisher","first-page":"9761","DOI":"10.1021\/acs.nanolett.1c03708","volume":"21","author":"T Wan","year":"2021","unstructured":"Wan T, Pan Q, Liu C, Guo J, Li B, Yan X, et al. A duplex CRISPR-Cas9 ribonucleoprotein nanomedicine for colorectal cancer gene therapy. Nano Lett. 2021;21:9761\u201371. https:\/\/pubmed.ncbi.nlm.nih.gov\/34767372\/.","journal-title":"Nano Lett"},{"key":"1070_CR291","unstructured":"https:\/\/crisprmedicinenews.com\/news\/oral-trap1-targeting-crispr-therapy-boosts-colorectal-cancer-treatment-in-multiple-disease-models\/ News: Oral TRAP1-Targeting CRISPR Therapy Boosts Colorectal Cancer Treatment in Multiple Disease Models - CRISPR Medicine."},{"key":"1070_CR292","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","volume":"11","author":"H Dana","year":"2020","unstructured":"Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, et al. CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B. 2020;11:1129. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8144892\/.","journal-title":"Acta Pharm Sin B"},{"key":"1070_CR293","unstructured":"https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI. 2025."},{"key":"1070_CR294","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9226391\/.","journal-title":"Front Immunol"},{"key":"1070_CR295","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-024-01568-z","volume":"17","author":"R Zheng","year":"2024","unstructured":"Zheng R, Zhu X, Xiao Y. Advances in CAR-T-cell therapy in T-cell malignancies. J Hematol Oncol. 2024;17:1\u201319. https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01568-z.","journal-title":"J Hematol Oncol"},{"key":"1070_CR296","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/s41375-023-01950-9","volume":"37","author":"S Neldeborg","year":"2023","unstructured":"Neldeborg S, Soerensen JF, M\u00f8ller CT, Bill M, Gao Z, Bak RO, et al. Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo. Leukemia. 2023;37:1792\u2013801.","journal-title":"Leukemia"},{"key":"1070_CR297","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1158\/1078-0432.CCR-22-1618","volume":"28","author":"P Jin","year":"2022","unstructured":"Jin P, Jin Q, Wang X, Zhao M, Dong F, Jiang G, et al. Large-scale in vitro and in vivo CRISPR-Cas9 knockout screens identify a 16-gene fitness score for improved risk assessment in acute myeloid leukemia. Clin Cancer Res. 2022;28:4033\u201344.","journal-title":"Clin Cancer Res"},{"key":"1070_CR298","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/s41375-023-01950-9","volume":"37","author":"S Neldeborg","year":"2023","unstructured":"Neldeborg S, Soerensen JF, M\u00f8ller CT, Bill M, Gao Z, Bak RO, et al. Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo. Leuk. 2023;37:1792. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10457201\/.","journal-title":"Leuk"},{"key":"1070_CR299","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/abbs\/gmr082","volume":"43","author":"N Giri","year":"2011","unstructured":"Giri N, Tomar P, Karwasara VS, Pandey RS, Dixit VK. Targeted novel surface-modified nanoparticles for interferon delivery for the treatment of hepatitis B. Acta Biochim Biophys Sin (Shanghai). 2011;43:877\u201383. https:\/\/pubmed.ncbi.nlm.nih.gov\/21914636\/.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"1070_CR300","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10142-025-01615-z","volume":"25","author":"AM Ayoub","year":"2025","unstructured":"Ayoub AM, Mahmoud EAB, Mohamed RH, Tolba MM, Hassan NS, Ghazy M, et al. BIRC5 as a master regulator in HCC: unraveling its role in tumor survival and therapeutic potential. Funct Integr Genomics. 2025;25:1\u201316. https:\/\/link.springer.com\/article\/10.1007\/s10142-025-01615-z.","journal-title":"Funct Integr Genomics"},{"key":"1070_CR301","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1272850","volume":"11","author":"X Ren","year":"2023","unstructured":"Ren X, Su D, Shi D, Xiang X. The improving strategies and applications of nanotechnology-based drugs in hepatocellular carcinoma treatment. Front Bioeng Biotechnol. 2023;11:1272850.","journal-title":"Front Bioeng Biotechnol"},{"key":"1070_CR302","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-025-00658-z","volume":"14","author":"X Yu","year":"2025","unstructured":"Yu X, Zhang Q, Wang L, Zhang Y, Zhu L. Engineered nanoparticles for imaging and targeted drug delivery in hepatocellular carcinoma. Exp Hematol Oncol. 2025;14:1\u201318. https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00658-z.","journal-title":"Exp Hematol Oncol"},{"key":"1070_CR303","doi-asserted-by":"publisher","first-page":"965","DOI":"10.7150\/thno.102964","volume":"15","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, Sun W, Xie J, Zhang Z, Luo J, Han X, et al. RNA nanotherapeutics for hepatocellular carcinoma treatment. Theranostics. 2025;15:965. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11700867\/.","journal-title":"Theranostics"},{"key":"1070_CR304","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-020-01603-0","volume":"39","author":"X Wu","year":"2020","unstructured":"Wu X, Ma W, Mei C, Chen X, Yao Y, Liu Y, et al. Description of CRISPR\/Cas9 development and its prospect in hepatocellular carcinoma treatment. J Exp Clin Cancer Res. 2020;39:1\u201311. https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-020-01603-0.","journal-title":"J Exp Clin Cancer Res"},{"key":"1070_CR305","volume":"18","author":"S Yu","year":"2023","unstructured":"Yu S, Zhao R, Zhang B, Lai C, Li L, Shen J, et al. Research progress and application of the CRISPR\/Cas9 gene-editing technology based on hepatocellular carcinoma. Asian J Pharm Sci. 2023;18:100828. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10424087\/.","journal-title":"Asian J Pharm Sci"},{"key":"1070_CR306","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202001424","volume":"7","author":"Y Qi","year":"2020","unstructured":"Qi Y, Liu Y, Yu B, Hu Y, Zhang N, Zheng Y, et al. A lactose-derived CRISPR\/Cas9 delivery system for efficient genome editing in vivo to treat orthotopic hepatocellular carcinoma. Adv Sci. 2020;7:2001424. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7507475\/.","journal-title":"Adv Sci"},{"key":"1070_CR307","doi-asserted-by":"crossref","unstructured":"Hu Y, Setayesh T, Vaziri F, Wu X, Hwang ST, Chen X, et al. miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism. Molecular Therapy. 2023;31:1829\u201345. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1525001623002538.","DOI":"10.1016\/j.ymthe.2023.04.019"},{"key":"1070_CR308","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3892\/ol.2024.14674","volume":"28","author":"M Wang","year":"2024","unstructured":"Wang M, Wang X, Wang Y, Gai Y, Ye J, Xu X, et al. Advances in the study of the mechanism of action of miR 22 in liver lesions (Review). Oncol Lett. 2024;28:541. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11413475\/.","journal-title":"Oncol Lett"},{"key":"1070_CR309","first-page":"193","volume":"17","author":"MA Younis","year":"2024","unstructured":"Younis MA, Harashima H. Understanding gene involvement in hepatocellular carcinoma: implications for gene therapy and personalized medicine. Pharm Pers Med. 2024;17:193. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11088404\/.","journal-title":"Pharm Pers Med"},{"key":"1070_CR310","doi-asserted-by":"publisher","first-page":"439","DOI":"10.32604\/or.2023.044473","volume":"32","author":"E Amjad","year":"2024","unstructured":"Amjad E, Pezzani R, Sokouti B. A review of the literature on the use of CRISPR\/Cas9 gene therapy to treat hepatocellular carcinoma. Oncol Res. 2024;32:439. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10865741\/.","journal-title":"Oncol Res"},{"key":"1070_CR311","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211006950","volume":"13","author":"M Gu","year":"2021","unstructured":"Gu M, Xu T, Chang P. KRAS\/LKB1 and KRAS\/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas. Ther Adv Med Oncol. 2021;13:17588359211006950. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8072935\/.","journal-title":"Ther Adv Med Oncol"},{"key":"1070_CR312","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s12672-025-03383-5","volume":"16","author":"H Noormohamadi","year":"2025","unstructured":"Noormohamadi H, Soleimani Samarkhazan H, kargar M, Maroufi F, Servatian N, Davami F. CRISPR\/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook. Discov Oncol. 2025;16:1530. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12339858\/.","journal-title":"Discov Oncol"},{"key":"1070_CR313","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2023.213420","volume":"149","author":"S Pyreddy","year":"2023","unstructured":"Pyreddy S, Poddar A, Carraro F, Polash SA, Dekiwadia C, Murdoch B, et al. Targeting telomerase utilizing zeolitic imidazole frameworks as non-viral gene delivery agents across different cancer cell types. Biomater Adv. 2023;149:213420. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S2772950823001437.","journal-title":"Biomater Adv"},{"key":"1070_CR314","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1200734","volume":"11","author":"M Yi","year":"2023","unstructured":"Yi M, Wang M, Xu Y, Cao Z, Ling Y, Zhang Z, et al. CRISPR-based m6A modification and its potential applications in telomerase regulation. Front Cell Dev Biol. 2023;11:1200734.","journal-title":"Front Cell Dev Biol"},{"key":"1070_CR315","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1158\/0008-5472.CAN-21-2519","volume":"82","author":"S Sayed","year":"2022","unstructured":"Sayed S, Sidorova OA, Hennig A, Augsburg M, Cort\u00e9s Vesga CP, Abohawya M, et al. Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing. Cancer Res. 2022;82:3002. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9437569\/.","journal-title":"Cancer Res"},{"key":"1070_CR316","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s42003-023-05052-1","volume":"6","author":"G Jang","year":"2023","unstructured":"Jang G, Kweon J, Kim Y. CRISPR prime editing for unconstrained correction of oncogenic KRAS variants. Commun Biol. 2023;6:681. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10313713\/.","journal-title":"Commun Biol"},{"key":"1070_CR317","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.3390\/cancers15245766","volume":"15","author":"R Wang","year":"2023","unstructured":"Wang R, Yang Y, Wang L, Shi Q, Ma H, He S, et al. SOX2-OT binds with ILF3 to promote head and neck cancer progression by modulating crosstalk between STAT3 and TGF-\u03b2 signaling. Cancers. 2023;15:5766. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10742126\/.","journal-title":"Cancers"},{"key":"1070_CR318","doi-asserted-by":"publisher","first-page":"13293","DOI":"10.3390\/app132413293","volume":"13","author":"K Vukovic \u0110erfi","year":"2023","unstructured":"Vukovic \u0110erfi K, Vasiljevic T, Matijevic Glavan T. Recent advances in the targeting of head and neck cancer stem cells. Appl Sci. 2023;13:13293. https:\/\/www.mdpi.com\/2076-3417\/13\/24\/13293\/htm.","journal-title":"Appl Sci"},{"key":"1070_CR319","first-page":"1","volume":"5","author":"S Zhang","year":"2020","unstructured":"Zhang S, Xiong X, Sun Y. Functional characterization of SOX2 as an anticancer target. Signal Transduct Target Ther. 2020;5:1\u201317. https:\/\/www.nature.com\/articles\/s41392-020-00242-3.","journal-title":"Signal Transduct Target Ther"},{"key":"1070_CR320","doi-asserted-by":"crossref","unstructured":"Chi MN, Auriol J, J\u00e9gou B, Kontoyiannis DL, Turner JMA, De Rooij DG, et al. The RNA-binding protein ELAVL1\/HuR is essential for mouse spermatogenesis, acting both at meiotic and postmeiotic stages. 2011;22:2875\u201385. Available from: https:\/\/www.molbiolcell.org\/doi\/pdf\/10.1091\/mbc.e11-03-0212.","DOI":"10.1091\/mbc.e11-03-0212"},{"key":"1070_CR321","doi-asserted-by":"publisher","first-page":"14030","DOI":"10.3390\/ijms241814030","volume":"24","author":"J Akhtar","year":"2023","unstructured":"Akhtar J, Imran M, Wang G. CRISPR\/Cas9-mediated CtBP1 gene editing enhances chemosensitivity and inhibits metastatic potential in esophageal squamous cell carcinoma cells. Int J Mol Sci. 2023;24:14030. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10530806\/.","journal-title":"Int J Mol Sci"},{"key":"1070_CR322","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/genes11080921","volume":"11","author":"K Khalaf","year":"2020","unstructured":"Khalaf K, Janowicz K, Dyszkiewicz-Konwi\u0144ska M, Hutchings G, Dompe C, Moncrieff L, et al. CRISPR\/Cas9 in cancer immunotherapy: animal models and human clinical trials. Genes. 2020;11:921. https:\/\/www.mdpi.com\/2073-4425\/11\/8\/921\/htm.","journal-title":"Genes"},{"key":"1070_CR323","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113891","volume":"176","author":"X Xu","year":"2021","unstructured":"Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, et al. Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment. Adv Drug Deliv Rev. 2021;176:113891. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0169409X21002830.","journal-title":"Adv Drug Deliv Rev"},{"key":"1070_CR324","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1542811","volume":"15","author":"C Li","year":"2025","unstructured":"Li C, Cheng D, Li P. Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance. Front Oncol. 2025;15:1542811.","journal-title":"Front Oncol"},{"key":"1070_CR325","doi-asserted-by":"publisher","first-page":"115456","DOI":"10.1016\/j.biopha.2023.115456","volume":"167","author":"J Ning","year":"2023","unstructured":"Ning J, Chen L, Xiao G, Zeng Y, Shi W, Tanzhu G, et al. The protein arginine methyltransferase family (PRMTs) regulates metastases in various tumors: From experimental study to clinical application. Biomed Pharmacother. 2023;167:115456. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0753332223012544.","journal-title":"Biomed Pharmacother"},{"key":"1070_CR326","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-46370-0","volume":"15","author":"H Cai","year":"2024","unstructured":"Cai H, Zhang B, Ahrenfeldt J, Joseph JV, Riedel M, Gao Z, et al. CRISPR\/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam\/Cabs1 gene cluster expression. Nat Commun. 2024;15:1\u201318. https:\/\/www.nature.com\/articles\/s41467-024-46370-0.","journal-title":"Nat Commun"},{"key":"1070_CR327","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-024-01833-1","volume":"22","author":"M Tabibian","year":"2024","unstructured":"Tabibian M, Moghaddam FS, Motevaseli E, Ghafouri-Fard S. Targeting mRNA-coding genes in prostate cancer using CRISPR\/Cas9 technology with a special focus on androgen receptor signaling. Cell Commun Signal. 2024;22:1\u201320. https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-024-01833-1.","journal-title":"Cell Commun Signal"},{"key":"1070_CR328","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado7225","volume":"17","author":"H Teng","year":"2025","unstructured":"Teng H, Hang Q, Zheng C, Yan Y, Liu S, Zhao Y, et al. In vivo CRISPR activation screen identifies acyl-CoA-binding protein as a driver of bone metastasis. Sci Transl Med. 2025;17:eado7225. https:\/\/www.insideprecisionmedicine.com\/topics\/patient-care\/crispr-reveals-driver-of-bone-metastasis\/.","journal-title":"Sci Transl Med"},{"key":"1070_CR329","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63\u201389. https:\/\/pubmed.ncbi.nlm.nih.gov\/31068988\/.","journal-title":"World J Oncol"},{"key":"1070_CR330","unstructured":"Advances in Prostate Cancer Research - NCI. 2024. Available from: https:\/\/www.cancer.gov\/types\/prostate\/research."},{"key":"1070_CR331","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v16.i3.107834","volume":"16","author":"G Christodoulidis","year":"2025","unstructured":"Christodoulidis G, Bartzi D, Tsagkidou K, Dimaki A, Lazaridou L, Vakalou K, et al. CRISPR\/Cas9 gene editing in gastric cancer: Mechanisms, advances, and therapeutic potential. World J Gastrointest Pathophysiol. 2025;16:107834. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12476675\/.","journal-title":"World J Gastrointest Pathophysiol"},{"key":"1070_CR332","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-025-02000-1","volume":"27","author":"BA Lipert","year":"2025","unstructured":"Lipert BA, Siemens KN, Khan A, Airey R, Dam GH, Lu M, et al. CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance. Breast Cancer Res. 2025;27:1\u201317. https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-02000-1.","journal-title":"Breast Cancer Res"},{"key":"1070_CR333","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.3390\/ijms21093151","volume":"21","author":"U Unachukwu","year":"2020","unstructured":"Unachukwu U, Chada K, D\u2019Armiento J. High mobility group AT-Hook 2 (HMGA2) oncogenicity in mesenchymal and epithelial neoplasia. Int J Mol Sci. 2020;21:3151. https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3151\/htm.","journal-title":"Int J Mol Sci"},{"key":"1070_CR334","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.978533","volume":"12","author":"Z Wu","year":"2022","unstructured":"Wu Z, Huo X, Yang T, Liu K, Wu T, Feng Z, et al. CRISPR\/Cas9-3NLS\/sgHMGA2@PDA nanosystem is the potential efficient gene editing therapy for gastric cancer with HMGA2 high expression. Front Oncol. 2022;12:978533. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9479195\/.","journal-title":"Front Oncol"},{"key":"1070_CR335","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-025-03112-8","volume":"23","author":"X Liu","year":"2025","unstructured":"Liu X, Liu X, Luo X, Zhu M, Liu N, Li J, et al. Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade. J Nanobiotechnol. 2025;23:1\u201318. https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03112-8.","journal-title":"J Nanobiotechnol"},{"key":"1070_CR336","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/biomedicines12010238","volume":"12","author":"E Begagi\u0107","year":"2024","unstructured":"Begagi\u0107 E, Be\u010duli\u0107 H, \u0110uzi\u0107 N, D\u017eidi\u0107-Krivi\u0107 A, Pugonja R, Muharemovi\u0107 A, et al. CRISPR\/Cas9-mediated gene therapy for glioblastoma: a scoping review. Biomedicines. 2024;12:238. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10813360\/.","journal-title":"Biomedicines"},{"key":"1070_CR337","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/cancers15020396","volume":"15","author":"X Kang","year":"2023","unstructured":"Kang X, Wang Y, Liu P, Huang B, Zhou B, Lu S, et al. Progresses, Challenges, and Prospects of CRISPR\/Cas9 Gene-Editing in Glioma Studies. Cancers. 2023;15:396. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856991\/.","journal-title":"Cancers"},{"key":"1070_CR338","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jconrel.2022.09.046","volume":"351","author":"W Ruan","year":"2022","unstructured":"Ruan W, Jiao M, Xu S, Ismail M, Xie X, An Y, et al. Brain-targeted CRISPR\/Cas9 nanomedicine for effective glioblastoma therapy. J Controlled Release. 2022;351:739\u201351. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0168365922006411.","journal-title":"J Controlled Release"},{"key":"1070_CR339","doi-asserted-by":"publisher","unstructured":"Zou Y, Sun X, Yang Q, Zheng M, Shimoni O, Ruan W, et al. Blood-brain barrier\u2013penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Sci Adv. 2022;8:eabm8011. https:\/\/doi.org\/10.1126\/sciadv.abm8011.","DOI":"10.1126\/sciadv.abm8011"},{"key":"1070_CR340","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1356578","volume":"11","author":"F Greco","year":"2024","unstructured":"Greco F, Cosentino M, Marino F. The Italian breakthrough in CRISPR trials for rare diseases: a focus on beta-thalassemia and sickle cell disease treatment. Front Med. 2024;11:1356578. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10902426\/.","journal-title":"Front Med"},{"key":"1070_CR341","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/cancers15061813","volume":"15","author":"D Stefanoudakis","year":"2023","unstructured":"Stefanoudakis D, Kathuria-Prakash N, Sun AW, Abel M, Drolen CE, Ashbaugh C, et al. The potential revolution of cancer treatment with CRISPR technology. Cancers. 2023;15:1813. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10046289\/.","journal-title":"Cancers"},{"key":"1070_CR342","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00262-025-04278-8","volume":"75","author":"Z Zhang","year":"2026","unstructured":"Zhang Z, Cui D, Wang H, Wu L, Liu X. Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy. Cancer Immunol Immunother. 2026;75:37. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12847500\/.","journal-title":"Cancer Immunol Immunother"},{"key":"1070_CR343","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12185-016-2031-1","volume":"104","author":"E Domingo-Musibay","year":"2016","unstructured":"Domingo-Musibay E, Yamamoto M. Gene- and Viro- therapy for Hematological Malignancies. Int J Hematol. 2016;104:29. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5089843\/.","journal-title":"Int J Hematol"},{"key":"1070_CR344","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1021\/acs.molpharmaceut.5c00474","volume":"22","author":"X Yi","year":"2025","unstructured":"Yi X, Jin X, Hu Y, Shen Z, Zheng X, Luo D, et al. Drug delivery systems for overcoming physical barriers in cancer therapy. Mol Pharm. 2025;22:6413\u201329. https:\/\/pubmed.ncbi.nlm.nih.gov\/41001833\/.","journal-title":"Mol Pharm"},{"key":"1070_CR345","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403. https:\/\/pubmed.ncbi.nlm.nih.gov\/36917948\/.","journal-title":"Cancer Cell"},{"key":"1070_CR346","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1808.","journal-title":"Cancer Cell"},{"key":"1070_CR347","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/cells14151136","volume":"14","author":"MA Rauf","year":"2025","unstructured":"Rauf MA, Rao A, Sivasoorian SS, Iyer AK. Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment: a comprehensive review. Cells. 2025;14:1136. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12346122\/.","journal-title":"Cells"},{"key":"1070_CR348","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","volume":"175","author":"I Jelcic","year":"2018","unstructured":"Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, et al. Memory B cells activate brain-homing, autoreactive CD4\u2009+\u2009T cells in multiple sclerosis. Cell. 2018;175:85\u2013100.e23. http:\/\/www.cell.com\/article\/S0092867418310274\/fulltext.","journal-title":"Cell"},{"key":"1070_CR349","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1007\/s12672-025-03529-5","volume":"16","author":"H Nourmohammadi","year":"2025","unstructured":"Nourmohammadi H, Babashahi M, Panji M, Radmehr S. Gene-edited hematopoietic stem cells for leukemia and lymphoma treatment: a systematic review of preclinical and translational evidence. Discov Oncol. 2025;16:1804. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12491117\/.","journal-title":"Discov Oncol"},{"key":"1070_CR350","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-026-00899-y","volume":"14","author":"Y Gao","year":"2026","unstructured":"Gao Y, Hu J, An N, Wen X, Li C. In vivo engineering of CAR-T cells: delivery strategies and clinical translation. Biomark Res. 2026;14:23. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12857126\/.","journal-title":"Biomark Res"},{"key":"1070_CR351","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.155","volume":"3","author":"W Zhou","year":"2022","unstructured":"Zhou W, Yang J, Zhang Y, Hu X, Wang W. Current landscape of gene-editing technology in biomedicine: applications, advantages, challenges, and perspectives. MedComm 2022;3:e155. https:\/\/doi.org\/10.1002\/mco2.155.","journal-title":"MedComm"},{"key":"1070_CR352","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.ymthe.2023.01.005","volume":"31","author":"BJ Booth","year":"2023","unstructured":"Booth BJ, Nourreddine S, Katrekar D, Savva Y, Bose D, Long TJ, et al. RNA editing: expanding the potential of RNA therapeutics. Mol Ther. 2023;31:1533. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9824937\/.","journal-title":"Mol Ther"},{"key":"1070_CR353","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szaf016","volume":"14","author":"J Rainaldi","year":"2025","unstructured":"Rainaldi J, Mali P, Nourreddine S. Emerging clinical applications of ADAR-based RNA editing. Stem Cells Transl Med. 2025;14:szaf016. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12105611\/.","journal-title":"Stem Cells Transl Med"},{"key":"1070_CR354","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1057\/s41599-022-01147-y","volume":"9","author":"M Almeida","year":"2022","unstructured":"Almeida M, Ranisch R. Beyond safety: mapping the ethical debate on heritable genome editing interventions. Humanit Soc Sci Commun. 2022;9:1\u201314. https:\/\/www.nature.com\/articles\/s41599-022-01147-y.","journal-title":"Humanit Soc Sci Commun"},{"key":"1070_CR355","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1015996","volume":"2022","author":"EO Ansah","year":"2022","unstructured":"Ansah EO. Ethical challenges and controversies in the practice and advancement of gene therapy. Adv Cell Gene Ther. 2022;2022:1015996. https:\/\/doi.org\/10.1155\/2022\/1015996.","journal-title":"Adv Cell Gene Ther"},{"key":"1070_CR356","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3906\/biy-1912-52","volume":"44","author":"FB Ayano\u011flu","year":"2020","unstructured":"Ayano\u011flu FB, El\u00e7\u0130n AE, El\u00e7\u0130n YM. Bioethical issues in genome editing by CRISPR-Cas9 technology. Turkish J Biol. 2020;44:110. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7129066\/.","journal-title":"Turkish J Biol"},{"key":"1070_CR357","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s43441-023-00574-6","volume":"58","author":"M Ghadanian","year":"2024","unstructured":"Ghadanian M, Schafheutle E. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations. Ther Innov Regul Sci. 2024;58:79\u2013113. https:\/\/link.springer.com\/article\/10.1007\/s43441-023-00574-6.","journal-title":"Ther Innov Regul Sci"},{"key":"1070_CR358","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bcp.14130","volume":"86","author":"R Joppi","year":"2019","unstructured":"Joppi R, Bertele V, Vannini T, Garattini S, Banzi R. Food and Drug Administration vs European Medicines Agency: review times and clinical evidence on novel drugs at the time of approval. Br J Clin Pharm. 2019;86:170. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6983504\/.","journal-title":"Br J Clin Pharm"},{"key":"1070_CR359","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1158\/1078-0432.CCR-24-2329","volume":"31","author":"N Chaudhary","year":"2025","unstructured":"Chaudhary N, La Ferlita A, Choudhary BS, Jog E, Kazi M, Yahya S, et al. Patient-derived organoids and xenografts uncover therapeutic vulnerabilities in colorectal signet ring cell carcinomas. Clin Cancer Res. 2025;31:1359\u201373. https:\/\/pubmed.ncbi.nlm.nih.gov\/39879477\/.","journal-title":"Clin Cancer Res"},{"key":"1070_CR360","first-page":"263","volume":"2","author":"E Wang","year":"2022","unstructured":"Wang E, Xiang K, Zhang Y, Wang XF. Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): new opportunities in establishing faithful pre-clinical cancer models. J Natl Cancer Cent. 2022;2:263\u201376. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2667005422000679.","journal-title":"J Natl Cancer Cent"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01070-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:03:06Z","timestamp":1790632986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01070-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":360,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1070"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01070-3","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All data were generated in-house, and no paper mill was used. All authors agree to be accountable for all aspects of work ensuring integrity and accuracy.","order":2,"name":"Ethics","label":"Credit author statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}